

CURRICULUM VITAE

of

Prof. Shyam Sundar

Address for Correspondence:

Dr Shyam Sundar

6 SK Gupta Nagar

Lanka, Varanasi – 221005

Email: drshyamsundar@hotmail.com

CURRICULUM VITAE

1. Name **SHYAM SUNDAR**
2. Date of birth 30 November, 1953
3. Marital Status Married
4. Father's name: Late Shri Ram Kishan Prasad Makharia
5. Address 6, SK Gupta Nagar, Lanka, Varanasi - 221 005 (India)
6. Present position Distinguished Professor of Medicine
Institute of Medical Sciences
Banaras Hindu University
Varanasi - 221 005 (India)
7. Phone Mobile - +91 9453048500
8. Email drshyamsundar@hotmail.com
drshyamsundar53@gmail.com

Educational Qualifications :

M.B.B.S. (Medical Sciences)	Institute of Medical Sciences BanarasHinduUniversity (BHU), Varanasi, India	1976
M.D. (Medicine)	Institute of Medical Sciences BanarasHinduUniversity (BHU), Varanasi, India	1981

Employment

Name of Employer/ Institution	Dates	Designation
Institute of Medical Sciences Banaras Hindu University	Jan, 1997 - June 2019 July 2019 – Life-long	Professor of Medicine Distinguished Professor of Medicine
-----do----- \ -----do-----	April 2001 – April 2004	Head, Department of Medicine x
-----do-----	Apr, 1990 - Jan, 1997	Reader in Medicine
-----do-----	Mar. 1981 - Apr; 1990	Lecturer in Medicine
----do-----	March 1997- Feb, 2003	Professor in charge, Center of Experimental Medicine and Surgery
----do-----	April 2001- April 2004	Head, Department of Medicine
----do-----	August 2018 – Nov, 2018	Dean Faculty of Medicine,

ART Center, SS Hospital Banaras Hindu University	2004 – 2018	Nodal Officer
Kala-azar Medical Research Center,	1994- till Date	Hon Director
Center of Excellence (HIV)	2009 – 2018	Programme Director
Infectious Diseases Research Laboratory, Deptt of Medicine Institute of Medical Sciences, Banaras Hindu University	1994- till date	Programme Director

Important Fellowships:

-Fellow (FRCP)	Royal College of Physicians, London
-Fellow (FAMS)	National Academy of Medical Sciences, India
-Fellow (FNASc)	National Academy of Sciences, India
-Fellow (FASc)	Indian Academy of Sciences, India
-Fellow (FNA)	Indian National Science Academy, India
-Fellow (FTWAS)	The World Academy of Sciences, Italy
- <u>ASTMH Distinguished International Fellow</u>	American Society of Tropical Medicine & Hygiene
-Honorary Fellow	Academy of Medicine of Malaysia

AWARDS/HONORS

International:

- 1. Honorary Fellow:** **Academy of Medicine of Malaysia, 2023**
- 2. India Leader Award (Microbiology):** **:Research.com. 2022**
- 3. Distinguished International Fellow:****American Society of Trop Med & Hygiene USA, 2017**
- 4. Fellow :** **The World Academy of Sciences, Italy 2016**
- 5. Anne Maurer Cecchini Award:** **Anne Maurer Foundation, Geneva Switzerland, 2010**
- 6. Fellow :** **Royal College of Physicians, London UK, 2004**
- 7. IDSA AIDS Fellowship:** **Infectious Diseases Society of America, 1994**

National Awards & Honors:

- 8. API Outstanding Achievers Award - Association of Physicians of India 2024**
- 9. Dr A Murgunathan Oration** : Association of Physicians of India (Tamilnadu Chapter) 2022
- 10. Prof BB Thakur Oration** : Association of Physicians of India

(Bihar Chapter) 2022

11. **Dr Bankat Chandra Memorial 2022 Oration** : Indian Medical Association (Hyderabad)
12. **Goyal Prize** : Goyal Founation, Kurukshetra University 2021
13. **Dr PN Cuttani Oration** : National Academy of Medical Sciences, 2021
14. **RK Biswas Oration** : Association of Physicians of India WB 2021
15. **Distinguished Scientist Award** : VDGOD Professional Association, 2020
16. **Faculty Research Award** : Careers 360 & Manipal Academy of Higher Education 2018
17. **ISCR Award** : Indian Society of Clinical Research 2018
18. **MG Alexander Award** : Clinical Infectious Diseases Society of India, 2017
19. **VASVIK Indus. Research Award** : VASVIK Trust, Mumbai 2017
20. **Visitor's Award (Research)** : President of the Republic of India, 2016
21. **Dr Jivraj Mehta Award** : Association of Physicians of India, 2016
22. **BR Ambedkar Centenary Award** : Indian Council of Medical Research, 2016
23. **Prof Hari Vaishnav Oration** : Association of Physicians of India 2016 (Delhi State Chapter)
24. **Vice-Chancellor's Award for Excellence in Research (Highest Category)** : Banaras Hindu University, 2014
25. **Shri Lallan Prasad Memorial Award** : Indian Medical Association (Varanasi) 2014
26. **Dr PN Raju Oration Award 2010** : Indian Council of Medical Research, 2013
27. **Prof MP Mehrotra Oration** : Association of Physicians of India (UP Chapter) 2013
28. **Prof CNR Rao Award** : CNR Rao Education Foundation 2013
29. **USV RAPICON Oration Award** : Railway Association of Physicians of India 2012
30. **Vice Chancellor Med Res Award** : Banaras Hindu University, 2010
31. **Dr VR Joshi Award** : Journal of Asso. of Physicians of India, 2009

32. **Netaji Oration** : Association of Physicians of India, 2006
33. **Ranbaxy Research Award** : Ranbaxy Science Foundation, 2002
34. **Dr Kamla Menon Medical Research Award** : Indian Council of Medical Research 1996
35. **Dr Coelho Memorial Oration** : Association Of Physicians Of India, 1995
36. **Dr. M. J. Shah Memorial Award** : Association of Physicians of India, 1994
37. **Shri Lallan Prasad Memorial Award** : India Medical Association, Varanasi 2014
38. **Dr MP Mehrotra Oration** : Association of Physicians of India (UP Chapter) 2013
39. **Order of Academic Excellence** : Institute of Medical Sciences, BHU 2013, 2014, 2015, 1. 2016, 2017, 2018
40. **Eminent Physician Award** : Association of Physicians of India (Varanasi Chapter)
2013
41. **PC Sengupta Memorial Oration** : School of Tropical Medicine, Kolkata 2011
42. **Dr S Nath Memorial Award** : Indian Medical Association, 2011
43. **Vice-Chancellor's Medical Research Award** : Banaras Hindu University, 2010
44. **IAMS Chairman Appreciation Award** : Indian Academy of Medical Specialities, 2008
45. **Best Teacher Award** : Indian Medical Association, Varanasi 2006
46. **DB Chandra Oration** : MLN Medical College Alumni Assoc., Allahabad, 2005
47. **Dr Rajendra Prasad Memorial Oration** : RMR Institute of Medical Sciences (ICMR) 2001
48. **Dr. N. N. Gupta Award** : Associations of Physicians of India, (U.P. Chapter), 1993
49. **Visiting Professor** : Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry
50. **Fellow (FAMS)** : **National Academy of Medical Sciences, India**
51. **Fellow (FNASc)** : **National Academy of Sciences, India**
52. **Fellow (FASc)** : **Indian Academy of Sciences, India**

53. Fellow (FNA)

:Indian National Science Academy, India

Dr Shyam Sundar currently figures among 2% Top Scientists in World in Tropical Medicine in the years 2020-23 as per the study conducted by Stanford University, USA.

Dr Shyam Sundar was ranked first in India and seventh in the world in the field of Tropical Medicine by Stanford University, California USA, 2020-2023

Author: *Davidson's Principle and Practice of Medicine, 20th-25th Editions*

Harrison's Principle of Internal Medicine – 18th -23rd Editions

Davidson's Clinical Cases, 2008

Conn's Current Therapy, 2002

Manson's Tropical Diseases, 2014, 2022

Nelson Textbook of Pediatrics: First South Asia Edition

API textbook of Medicine

Postgraduate Text book of Pediatrics - Ed Piyush Gupta et al.

Important Media Coverage of the Work:

Exclusive television documentaries

Journeyman.tv (Discovery channel) Documentary MILTEFOSINE on you tube -

<https://www.youtube.com/watch?v=O1DLDw31g7I>

<https://www.youtube.com/watch?v=vr-01IPiz0g>

Al Jazeera doc: The Pulse "Teaching an old drug new tricks" : Kala azar (visceral leishmaniasis)

PM - <https://www.youtube.com/watch?v=l6tKIH2COSs&t=179s>

Kala Azar: Kill or Cure BBC Documentary Part 2 (Visceral Leishmaniasis) Prof. Shyam Sundar,

India - <https://www.youtube.com/watch?v=wY43zsHfsVU&t=294s>

Kala Azar: Kill or Cure BBC Documentary series 1 - (Visceral Leishmaniasis) Prof. Shyam

Sundar, India - <https://www.films.com/id/20164>

Important contributions of Dr Shyam Sundar

- His pioneering work on **rapid rK39 strip test** resulted in the global application of this tool for the **diagnosis of kala-azar**, and it is being used in the national programmes of India and several countries of the world.
- He described several breakthroughs in the **treatment of kala-azar**, and developed first orally effective drug “**miltefosine**” for the treatment of VL. Miltefosine was used for the Kala-azar Elimination Programme in India, Nepal and Bangladesh, and now it is being used worldwide.
- He led the pivotal **paromomycin** trial, based on which the drug was approval by the Government of India.
- He has also done excellent work on lipid associated amphotericin B. His work with **single dose liposomal amphotericin B** is considered as a major breakthrough in the treatment of VL, and has earned worldwide acclaim. This single dose regimen is now the most preferred according to WHO recommendations, and it is being used in the control programmes in India, Nepal & Bangladesh.
- Dr Shyam Sundar was first to successfully conduct **multidrug therapy** of VL, and these regimens are also approved by WHO as the second most preferred regimen. Combination of paromomycin and miltefosine is also being used at primary health centers by the National Control Programme.
- He demonstrated successful treatment of post kala-azar dermal leishmaniasis with Liposomal Amphotericin B alone for 2 weeks or combined with oral miltefosine for 3 weeks as opposed to previously prevalent 12 weeks to 4 months treatment.

Publication Highlights:

<i>h</i>-index	:	105(Google Scholar)
<i>i10</i>-index	:	459
Citations	:	>45,000
Total Publications	:	66

Ten Selected publications of Dr Shyam Sundar

1. Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, Rowton E, Chaubey R, Singh AK, Rai TK, Fay MP, Chakravarty J, Sacks D, **Sundar**

S.Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. *Lancet Microbe*. 2021 Jan;2(1):e23-e31. doi: 10.1016/S2666-5247(20)30166-X.PMID: 33615281

2. **Sundar S**, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. *Lancet*. 2011; 377 :477-86.
3. **Sundar S**, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. *N Engl J Med*.2010; 362: 504-12.
4. **Sundar S**, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. *N Engl J Med*. 2007; 356:2571-81.
5. **Sundar S**, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.Oral miltefosine for Indian visceral leishmaniasis. *N Engl J Med*. 2002; 347: 1739-46.
6. **Sundar S**, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. *BMJ*. 2001; 323: 419-22.
7. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. *N Engl J Med*. 1999; 341: 1795-800. Shared first authorship.
8. **Sundar S**, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. *Lancet*. 1998; 352: 1821-3.
9. **Sundar S**, Reed SG, Singh VP, Kumar PC, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. *Lancet*. 1998; 351: 563-5.
10. **Sundar S**, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. *Clin Infect Dis*. 2000; 31: 1104-7.

RESEARCH GRANTS (In Indian National Rupees)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA, VisceralLeishmaniasis in Bihar State, India - 146 Million rupees (2007-12) and 130 millionrupees (2012-17), 180 millionrupees (2017-2022)

London School of Hygeine and Tropical Medicine/ Bill & Melinda Gates Foundation -

Setting the Post-Elimination Agenda for Kala-Azar in India (**SPEAK India**) The primary objective of this project is to develop and validate an innovative set of tools for VL case finding and surveillance that can be applied within the context of the Indian healthcare system (2019-2020; 20 million rupees)

Bill & Melinda Gates Foundation

Xenodiagnosis of Visceral Leishmaniasis, Post Kala-azar Dermal Leishmaniasis and Asymptomatic subjects using Phlebotomine Sand Flies – 31 million rupees (2015-2018)

Department of Science and Technology, Government of India Nano project - Synthesis and application of nano materials towards energy and EMI shielding, targeted drug delivery and theranostic application of biocompatible micro particle derived from human platelet for nano therapeutics. (6 million)

The Foundation for the National Institutes of Health (FNIH), USA

Epidemiology of Visceral Leishmaniasis in Muzaffarpur District, Bihar (Epi VL) – 5.7 million rupees (2014-2016)

Indo-Australian Biotechnology Fund:

Designing combination immunotherapy and drug treatment to control chronic infectious diseases - 14 million rupees.

European Commission:

New tools for monitoring drug resistance and treatment response in Visceral Leishmaniasis in the Indian subcontinent (KALADRUG-R) – 25 million rupees

World Health Organisation/Tropical Diseases Research:

An Evaluation of Health System in Delivering Health Care in Visceral Leishmaniasis – 2.4 million rupees

Indian Council of Medical Research

Comparative Evaluation of PCR Primers In Diagnosis and Prognosis of Indian Visceral Leishmaniasis (VL) and Post Kala-Azar Dermal Leishmaniasis (PKDL) – 2 million rupees

European Commission:

Efficacy, acceptability and cost-effectiveness of long lasting insecticide treated nets in the prevention of Kala-azar – 25 million rupees

Infectious Diseases Research Institute/Bill & Melinda Gates Foundation

A phase I, open-label, dose-escalating study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine (recombinant three-antigen *Leishmania* polyprotein with adjuvant MPL-SE) in healthy adults in india – 6.5 million rupees

World Health Organisation/Tropical Diseases Research

A Phase III Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of injectable Paromomycin in Patients with Visceral Leishmaniasis

Field Evaluation of novel diagnostic tests for Visceral Leishmaniasis: freeze dried DAT, rK39, rK26 dipsticks and KAtex (latex agglutination urine test)

Visceral Leishmaniasis and PKDL in India: New Therapeutic, Immunologic and Diagnostic Studies, and Site Preparation for Vaccine Trial - a multiinstitutional project involving BHU, CDRI, IICB and RMRI (Project Leader – Dr Shyam Sundar)

“Treatment of visceral leishmaniasis with the orally administrable agent miltefosine: a rising dose, phase II trial”

"Immunochemotherapy for visceral leishmaniasis interferon-gamma plus antimony"

A Phase III Clinical trial to assess efficacy and safety of orally administered miltefosine in children with visceral leishmaniasis

A Study of HIV/VL Co-infection

A Phase III Clinical trial to assess efficacy and safety of orally administered miltefosine in patients with visceral leishmaniasis with Control group: Amphotericin B

A phase II trial of short course amphotericin B and Fat emulsion in the treatment of Indian kala-azar

A multicenter phase II trial of miltefosine in Indian Visceral Leishmaniasis.

A Phase II Clinical trial to assess efficacy and safety of orally administered miltefosine in children with visceral leishmaniasis

Joint Indo-US Vaccine Action Programme.

"Immunologic and parasitologic studies of Indian Visceral Leishmaniasis"

NIH/National Institute of Allergy and Infectious Diseases

Bethesda, MD, USA AND DEPARTMENT OF BIOTECHNOLOGY, GOVT OF INDIA

Rockefeller Foundation, New York, USA :

"Immunochemotherapy for Indian visceral leishmaniasis: randomized controlled three-arm trial of treatment with 30 days of antimony alone vs. 30 days of antimony plus interferon- γ vs. 15 days of antimony plus interferon-t."

Indian Council of Medical Research :

"Effect of recombinant human gamma interferon therapy in antimony resistant kala-azar - a clinical and immunological study".

TRAINING FELLOWSHIP ABROAD

-UGC foreign Travel Fello-

University Grants Commission, 1993

workshop for training at
The New York Hospital,
New York, USA

-AIDS Training fellowship,
Memorial Sloan Kettering
Hospital, New York, USA

Infectious Diseases Society Of America, 1994

-WHO Workshop
at CASABLANCA, Morocco

WHO/TDR & NIH/NIAID USA Sponsored
typing workshop on leishmania 1995

-WHO/UNAIDS Workshop
at Mae Sot, Thailand

Training Workshop on Good Clinical Practices (GCP) for
Clinical Monitors from Asian Countries, 1999

- WHO Workshop
at Addis Ababa, Ethiopia

WHO/CTD Sponsored - HIV/Visceral Leishmaniasis
Co-infection Voluntary Counselling and Training, 1999

-WHO fellowship at Bangkok,
Thailand

Advanced training of second line ARV drugs 2008

**Positions in associations, committees , Advisory Groups,
Commissions etc. Past and present.**

Chairman

**Credential Committee, Indian College of Physician, API
2024**

President

Association of Physicians of India (2022-2023)

Chairman

Indian College of Physicians (2022-2023)

Chairman

Physicians Research Foundation (2022-2023)

President

Clinical Infectious Diseases Society of India (2016-17)

President

Leishmania Research Society, India

Member

Expert Committee on clinical trials, ICMR, Delhi

Member
Geneva,

Diagnostic Technical Advisory Group (DTAG) WHO,
Switzerland

Member

Guideline Development Group (GDG) WHO, Geneva,
Switzerland

Chairman

Scientific Advisory Committee, Indira Gandhi Institute of Medical
Sciences, Patna

Chairman

Scientific Committee, APICON 2021-2022

Editor	Journal of Tropical Medicine
Editor	Infectious Diseases of Poverty
Editor	Journal of Global Infectious Diseases
Editor	PLoS Neglected Tropical Diseases
Member	Council of Indian National Science Academy
Member	World Health Organization (WHO) Expert Advisory Panel on Parasitic Diseases
Member	Institute Body& Governing Council, Sree Chitra Tirunal Institute for Medical Sciences & Technology Thiruvananthapuram
Member	Academic Council, UP University of Medical Sciences, Saifai.
Member	WHO, Geneva Expert Panel on leishmaniasis
Member	TDR, WHO Disease Reference Group
Member	Scientific Advisor Committee, TDR, WHO Committee on VL Elimination
Member	Govt of India, Ministry of Health Expert Committee on Kala-azar
Editor-in-Chief	World Journal of Clinical Infectious Diseases (2015-2017)
Member, Editorial Board	World Journal of Immunology
Member, Editorial Board	Asian Journal of Medical Sciences
Member, Editorial Board	Infectious Diseases of Poverty
Member, Scientific Advisory Committee	Visceral Leishmaniasis, TDR/WHO, Geneva
Visiting Professor	Jawaharlal Institute of Post-graduate Medical Education and Research, Pondicherry
Founder President	Leishmania Research Society (India)
Member	Scientific Working Group of Leishmaniasis, TDR/WHO, Geneva 2004

Advisor	DNDi (Drugs for Neglected Diseases Initiative), Geneva
Member	AmBisome Consultative Group, WHO, Geneva 2005
Advisor	World Health Organization, SEARO, New Delhi
Chairman	Expert group on Diagnosis and Treatment of Kala-azar, Govt. of India
Advisor	Government of Nepal Expert Committee on leishmaniasis
Member,	Leishmaniasis Reference Group, World Health Organization/TDR, Geneva, Switzerland
Technical Expert	For leishmaniasis, Indian Council of Medical Research
Member	Project Review Committee, Indian Council of Medical Research
Expert	Technical committee on Antiretroviral Therapy, NACO, Govt. of India
Expert	Technical committee on Opportunistic Infections in HIV infection, NACO, Govt. of India
-Member, PDT of Miltefosine	World Health Organization/TDR, Geneva, Switzerland
-Member, PDT of Aminosidine	World Health Organization/TDR, Geneva, Switzerland
-Member, Scientific Advisory Committee	Institute of One World Health, San Francisco, USA
-Former Editor	International Journal of Infectious Diseases, New York, USA.
- Asst Editor,	Journal of the Association of Physicians of India
-Member, Scientific Advisory Committee	Institute of Pathology, New Delhi
-Member, Scientific Advisory Committee	Rajendra Memorial Institute of Medical Sciences, Patna
-Member	Physicians Research Foundation, API, 2016-20
-Member, Governing Body,	Association of Physicians of India, 2006-2011
- Chairman	Association of Physicians of India, (UP Chapter) 2008

- Member, Governing Body, Association of Physicians of India, (UP Chapter) 1994-96.
- Member Indian Society for Communicable Diseases
- Member Indian Medical Association
- Fellow (FICP) Indian College of Physicians
- Member American Society of Tropical Medicine & Hygiene
- Member Indian Society of Hematology and Blood Transfusion
- Member Indian Geriatric Society
- Member Association of Physicians of India

Details of delivering lectures/Chair of the session in International meetings abroad in last 15 years :

Year	Period	Lecture/Meeting/Workshop etc. and Place
------	--------	---

2009	March 25 to April 04	To deliver a lecture during “a preliminary meeting and training workshop” held at Dubrovnik, Croatia, Antwerp, Belgium
	Sept. 07 to Sept. 11	To deliver a lecture at 6 th congress on “Tropical Medicine and International Health, held at Verona –Italy
	Nov. 06 to Nov. 21	To participate as an invited speaker at the International Colloquium “Neglected Tropical Diseases of Latin America at Lima, Peru
2010	March 22 to 26	To deliver a lecture during WHO Expert Committee Meeting on Leishmaniasis Control Programme held at Geneva, Switzerland.
	June 22	To receive the Anne-Maurer Cecchini-2010 Award at Geneva Health Forum Geneva, Switzerland
	Aug. 16 – Sept 04	To participate as a Co-Chairman and Speaker at the XIIth International Congress of Parasitology (ICOPA), held at Melbourne, Australia
	Sept. 17 - 25	(i) To deliver a lecture at Neglected Global Diseases Initiative (NGDI) at the University of British Columbia (UBC), Vancouver, Canada. (17-20) (ii) To deliver a lecture during Annual meeting of Kala Drug at Paris, France (21-25)
	Nov. 03 - 07	To deliver a lecture at 59 th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) held at Atlanta, USA
2011	May 03- June 11	To deliver a lecture at IRID - TMRC Annual meeting at Bethesda North Marriott Hotel, Washington, USA.
	July 08 – July 10	To present a guest lecture during the ISID Neglected Tropical Diseases Meeting to be held at Boston
	Sept 12 - 23	To deliver a lecture at Annual Coordination Meeting of Kala-Drug-R held at the Charite University, Berlin, Germany
	Oct. 3 - 9	Invited as a speaker for the main session during the 7 th European Congress on Tropical Medicine and International Health held at Barcelona, Spain
2012	April 2 - 11	To deliver a lecture during the External Advisory Committee Meeting for the Bill & Melinda Gates Foundation, held at Seattle, USA
	May 14 – June 29	To deliver a lecture at IRID – TMRC Annual meeting at Bethesda North Marriott Hotel, Bethesda, USA.
	Sept. 23 - 27	To present two guest lectures in XVIII International Congress for Tropical Medicine and Malaria, held at the Royal Tulip Hotel Rio de Janeiro, Brazil

	Oct. 8 - 9	To deliver a lecture during one day meeting to develop FIND strategy on diagnostics for Leishmaniasis, held at FIND office, 16 Avenue, Geneva, Switzerland
	Dec. 4 - 8	To deliver a lecture during a meeting regarding collaboration on Leishmaniasis vaccines and diagnostics at Infectious Disease Research Institute (IDRI), Seattle, USA
2013	Jan. 22 - 24	To deliver a lecture during PKDL Working Groups Meeting held at Geneva, Switzerland
	March 24 - 28	To deliver a lecture at workshop on “Update on diagnostic and chemotherapeutic approaches against Leishmaniasis” held at Kolombo, Sri Lanka.
	May 13 - 17	To deliver a lecture at 5 th World Congress on Leishmaniasis” held at Porto de Galinhas Recife, Brazil
2014	Feb 25 – March 02	To visit Dr. Christian Engwerda, Queensland Institute of Medical Research, Herston, Australia to discuss the progress of joint Australia-India Strategic Research Grant and give a guest lecture’ held at Herston (Queensland), Australia.
	March 4 -6	To deliver a lecture and attend first Global Vaccine and Immunization Research Forum (GVIRF) held at Bethesda, Maryland, USA
	March 19 -20	To deliver a lecture and attend a workshop focused on anthroponotic visceral leishmaniasis (VL), held at Seattle, USA
	July 22 -23	To deliver a lecture and attend the Translational Funding Committee meeting hosted by Wellcome Trust, held at Wellcome Trust, London
	July 28 - 29	To deliver a lecture at the informal Expert Consultation meeting held at Kathmandu, Nepal
2015	Feb. 10 - 11	To deliver a lecture at Kala-azar elimination programme Partner’s meeting held at WHO-HQ Salle D, Geneva, Switzerland
	April 30	To conduct a Viva of Ph. D. defense at Institute of Tropical Medicine, Antwerp, Belgium
	Sept 5 – 8	To deliver a guest lecture at European Congress of Tropical Medicine & International Health, Basel, Switzerland
	Sept. 9 - 12	To deliver a guest lecture at NIH, Bethesda, USA
	Oct. 21 - 24	To deliver a lecture in the meeting of the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD) at Philadelphia, PA, USA
2016	Jan. 25 - 28	To deliver a lecture at the 2016 Keystone Symposia on Drug Discovery for Parasitic Diseases, held at Tahoe City, California, USA

	March 30 – April 01	To deliver a lecture at TDR/WHO expert meeting: Visceral Leishmaniasis (VL).....in the Indian Sub-continent held at Kathmandu, Nepal.
	Oct. 5 - 7	To deliver a lecture at Workshop on “Switching the Poles” organized by the Clinical Research Network, ITM, held at Antwerp, Belgium
	Nov. 13 - 17	To deliver a lecture at 65 th Annual Meeting of American Society of Tropical Medicine and Hygiene held at Atlanta, USA
2017	May 16 - 20	To deliver a lecture at 6 th World Congress on Leishmaniasis as an invited SPEAKER held at Toledo, Spain.
	Aug 21 – 23	To deliver a lecture and attend Kik-off meeting of TMRC at Gaithersburg, NIH, USA
	Oct. 16 - 20	To deliver a talk and co-chair a scientific session at the 10 th European Congress on Tropical Medicine and international Health (ECTMIH) to held at Antwerp, Belgium
	Oct. 20-31	To deliver a lecture at WHO Mission on Elimination Programme on Kala-Azar held at Dhaka, Bangladesh
	Nov. 5 - 9	To receive Honorary International Fellowship of American Society of Tropical Medicine & Hygiene and present a paper, to be held at Baltimore, Maryland, USA
2018	April, 19 - 25	To deliver a lecture at 28 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held at Madrid, Spain.
	May 13 - 17	To deliver a lecture at the PKDL (Post Kala-Azar Dermal Leishmaniasis) Consortium meeting) held at Colombo, Sri Lanka.
	Aug. 19 - 24	To deliver a lecture at 14 th International Congress of Parasitology (ICOPA-2018), held at Daegu, S. Korea
	Oct. 11 - 14	To deliver a lecture at DSMB meeting for the Miltefosine-Paromomycin Phase-III trial, held at Nairobi, Kenya.
	Oct. 25 – Nov.13	To deliver a lecture at 67 th Annual Meeting of American Society of Tropical Medicine and Hygiene (COR-NTD 2018) held at New Orleans, LA, USA
	Nov. 21 - 24	To deliver a lecture and chair a session – at WHO Symposium on Kala-Azar held at Kathmandu, Nepal
	Dec. 12 - 14	To deliver a lecture at Kala-Azar working group meeting and the meeting of Regional Technical Advisory Group (RTAG) on Elimination of Kala-azar held at Kathmandu, Nepal
2019	May 12 – 15	To give a presentation and deliver a lecture at a conference held at the University of Dundee, Scotland
	Nov. 20 – 24	To deliver a lecture at 68 th Annual Meeting of American Society of Tropical Medicine and Hygiene held at Harbor, Maryland, USA
2020	Nov 24	WHO Seminar - Neglected Tropical Diseases and One Health: gearing up against anti-microbial resistance to secure the safety of future generations -AMR in visceral leishmaniasis
2020	Nov 22	ICMR-NIMR & MERA-India Distinguished Lectures: Visceral Leishmaniasis: An update
2021	Nov. 11 - 12,	Invited lecture at ASTMH Clinical Pre-Meeting course

2022	14 – 17 July,	World of Leishmaniasis PKDL, CL & MCL: Invited lecture at annual meeting of Clinical Infectious Diseases Society of India – Kolkata Kolkata, India
2022	Aug 1-6	Delivered three lectures at 7 th World Congress on Leishmaniasis, Cartagena, Columbia. 3 August 2022: PKDL treatment – why it is important for VL control and elimination, and the need for improved treatments 3 August 2022: Diagnosis of visceral leishmaniasis in an elimination setting: a validation study of the diagnostic algorithm in India 4 August 2022: Efficacy and safety of short course combination regimens of Liposomal Amphotericin B and miltefosine for treatment of PKDL in the Indian subcontinent
2022	Oct	West Bengal Physicians of India Annual Conference Kolkata. An update on the treatment of visceral Leishmaniasis
2022	Nov	Annual Conference of the Rajasthan Physicians of India, Jaipur - Malaria Epidemic in India – An update
2022	Nov	Odisha Chapter annual Conf of Physicians of India, Bhubaneswar - History of evolution of the treatment of PKDL
2022	April	Presidential Oration: Kala-azar From One month to a single dose treatment. 77th Annual Meeting of Association of Physicians of India, Jaipur 15th April, 2022
2022	Nov	Dr. A Murgunathan Oration: 27 November 2022, Association of Physicians of India (Tamilnadu Chapter) Trichy. Emergence of drug resistance malaria
2022	Nov	Prof. B.B. Thakur Oration: Association of Physicians of India (Bihar Chapter) Muzaffarpur 2022 – Treatment of Kala-azar with Single Dose
2022	July	Dr. Bankat Chandra Memorial Oration: Indian Kala-azar – An Update. Indian Medical Association (Hyderabad) 2022
2022	Oct	Invited Lecture at 2nd South Zone & SMZ and 6th TSAPICON, Warangal Telangana 16th October 2022 - Kala-azar in India – An overview

2022	Nov	Annual Conference of Rajasthan Chapter of Association of Physicians of India , Jaipur 27 Nov 2022 Drug Resistant Malaria – An Update
2023	Jan	APICON (Association of Physicians of India Annual Meeting), Ahmedabad - Artemisinin resistance in Malaria – Global Scenario
2023	Oct	25 October Key Note address : VACCINES & INFECTIOUS DISEASES, Boston, USA, Treatment of Kala-azar – One month to One dose & Chaired session
2023	Nov	November 22 - Equity in health care: Practice models: Equitable care for Visceral Leishmaniasis in India, CMC, Vellore
2023	Nov	22 November - 15th International Short Course in Clinical Tropical Medicine at CMC Vellore – Visceral Leishmaniasis
2024	February	Invited Guest Lecture, Annual Spring meeting of British Society of Parasitology, Liverpool UK. 2-5 February 2024
2024	August	Two plenary lectures at the 33 rd annual meeting of SRI LANKA COLLEGE OF MICROBIOLOGISTS, Colombo Sri Lanka 14-16 August 2024

Conferences Attended -2022-23

- 1** **14 – 17 July, 2022 Kolkata, India World of Leishmaniasis PKDL, CL & MCL:** Invited lecture at annual meeting of Clinical Infectious Diseases Society of India – Kolkata
- 2** **Presidential Oration:** Kala-azar From One month to a single dose treatment. 77th Annual Meeting of Association of Physicians of India, Jaipur 15th April, 2022
- 3** **Dr. A Murgunathan Oration:** 27 November 2022, Association of Physicians of India (Tamilnadu Chapter) Trichy. Emergence of drug resistance malaria
- 4** **Prof. B.B. Thakur Oration:** Association of Physicians of India (Bihar Chapter) Muzaffarpur 2022
- 5** **Dr. Bankat Chandra Memorial Oration:** Indian Kala-azar – An Update. Indian Medical Association (Hyderabad) 2022
- 6** **Invited lectures at 7th World Congress on Leishmaniasis,** Cartagena, Colombia 2022

- 7 **4 August 2022:** Efficacy and safety of short course combination regimens of Liposomal Amphotericin B and miltefosine for treatment of PKDL in the Indian subcontinent
- 8 **3 August 2022:** PKDL treatment – why it is important for VL control and elimination, and the need for improved treatments
- 9 **3 August 2022:** Diagnosis of visceral leishmaniasis in an elimination setting: a validation study of the diagnostic algorithm in India
- 10 **Annual Conference of Rajasthan Chapter of Association of Physicians of India, Jaipur 27 Nov 2022** Drug Resistant Malaria – An Update
- 11 **Invited Lecture at 2nd South Zone & SMZ and 6th TSAPICON, Warangal Telangana 16th October 2022 - Kala-azar in India – An overview**
- 12 **Invited Lecture:** Drug Resistance in Malaria Annual Meeting of Association of Physicians of India, Ahmedabad 78th Annual Conference of the Association of Physicians of India 27 January, 2023.
- 13 **Invited Guest Lecture, Annual meeting of British Society of Parasitology, 3 March 2024, Liverpool, UK**
- 14 **Two plenary lectures** at the 33rd annual meeting of SRI LANKA COLLEGE OF MICROBIOLOGISTS, Colombo Sri Lanka 13-15 August 2024

Organised International/national CME/Updates/Conferences:

1. Org. Secretary, International Symposium on visceral leishmaniasis, 1996.
2. TDR/WHO sponsored International meeting on Control of Visceral Leishmaniasis in India, 1999
3. WHO sponsored Training Workshop on Management of Kala-azar for Physicians and Pediatricians of Nepal, 1999
4. WHO/TDR sponsored GCP (Good Clinical Practice) and Good Clinical Laboratory Practice training course, 2001
5. Coordinator – Seminar on Indian Perspectives in Tropical Diseases, 2002
6. Organising Secretary, Annual Conference of the Association of Physicians of India APICON – 2003
7. WHO/TDR meeting on Implementation Research, 2007
8. Annual Meeting of the Clinical Infectious Diseases Society of India, 2016

9. Organiser – 4th World congress on Leishmaniasis, Lucknow
10. Organising Chairman, CIDSCON, Annual Conference of Clinical Infectious Diseases Society of India, 2016

REVIEWER/EXPERT

1. New England Journal of Medicine
2. The Lancet
3. British Medical Journal
4. Wellcome Trust, London, U. K.
5. Israel Science Foundation, Jerusalem, Israel
6. Indian Council of Medical Research, New Delhi
7. Department of Biotechnology, Government of India
8. Department of Science and Technology, Government of India
9. Lancet Infectious Disease, UK
10. Clinical Infectious Diseases, USA
11. Infection and Immunity, USA
12. Antimicrobial Agents Chemotherapy, USA
13. Expert Review of Anti-infective Therapy, UK
14. Bull World Health Organisation, Geneva, Switzerland
15. International Journal of Infectious Diseases, New York, USA
16. Acta Tropica, Belgium
17. Transactions of the Royal Society of Tropical Medicine and Hygiene, UK
18. Experimental Parasitology, USA

19. Tropical Medicine & International Health, London, UK
20. Medical Science Monitor, USA
21. Parasite, JOUR-EN-JOSAS, France
22. Expert Opinion on Pharmacotherapy, London, UK
23. Expert Review of Anti-infective Therapy
24. Journal of Association of Physicians of India, Mumbai
25. Journal of Postgraduate Medicine, Mumbai
26. Journal of Parasitic Diseases, Chandigarh
27. Indian Journal of Dermato. Lepro. & Venereology
28. Indian Journal of Preventive & Social Medicine
29. Journal of Internal Medicine of India
30. Immunology
31. Tropical Doctor
32. Diagnostic Microbiology Infectious Diseases, USA
33. Applied Biochemistry and Biotechnology
34. Journal of Theoretical Biology
35. The Journal of Infectious Diseases
36. The Journal of Parasitology
37. Oriental Pharmacy and Experimental Medicine
38. Journal of the S. Paulo Institute of Tropical Medicine
39. Clinical and Experimental Immunology
40. Journal of Antimicrobial Chemotherapy
41. Expert Opinion Drug Delivery
42. Journal of Medical Microbiology, UK

43. The American Journal of Tropical Medicine and Hygiene
44. Journal of Occupational Medicine and Toxicology, Germany
45. Biochimie, France
46. PharmacoEconomics, New Zealand
47. Parasites & Vectors
48. Therapeutic Delivery
49. PLoS Neglected Tropical Diseases
50. the Bill & Melinda Gates Foundation
51. Journal of Parasitology and Vector Biology
52. Scientific Research and Essays
53. African Journal of Biotechnology
54. Parasitology International
55. Vaccine
56. Applied Biochemistry and Biotechnology
57. Journal of Theoretical Biology
58. Infection
59. Journal of Occupational Medicine and Toxicology
60. Applied Biochemistry and Biotechnology
61. Journal of Theoretical Biology
62. Clinical and Vaccine Immunology
63. Journal of Occupational Medicine and Toxicology
64. Expert Opinion on Drug Delivery
65. Diagnostic Microbiology and Infectious Disease.

List of Publications

Total Publications– 664

Publications in PubMed -554, *h-index*– 105, Citations - >45000

1. Kumar A, Singh VK, Madhukar P, Tiwari R, Roy R, Rajneesh, Mehrotra S, Sundar S, Kumar R. Evaluation of blood based quantitative PCR as a molecular diagnostic tool for post kala-azar dermal leishmaniasis (PKDL). Mol Biol Rep. 2024 Jun 1;51(1):716. doi: 10.1007/s11033-024-09640-0. PMID: 38824237.
2. Chaubey, Manaswi; Chakravarty, Jaya; Gupta, Rishabh; Jethwani, Parth; Puri, Rahul; Sundar, Shyam. Evaluation of Cardiovascular Risk Profile and Risk Scores of Antiretroviral Therapy-naïve HIV Patients in Eastern India. Journal of Global Infectious Diseases ():10.4103/jgid.jgid_29_24, August 07, 2024. | DOI: 10.4103/jgid.jgid_29_24
3. Cloots K, Singh OP, Singh AK, Rai TK, Tiwari VD, Neyaz A, Pandey S, Scholar VK, Malaviya P, Hasker E, Sundar S. Monitoring of Leishmania transmission in the post-elimination phase: the potential of serological surveys. Int J Infect Dis. 2024 Jun 25:107153. doi: 10.1016/j.ijid.2024.107153. Online ahead of print. PMID: 38936656
4. Sundar S, Chakravarty J. Recent Advances in the Treatment of Leishmaniasis. Pediatr Infect Dis J. 2024 Jun 21. doi: 10.1097/INF.0000000000004429. Epub ahead of print. PMID: 38907629.
5. Sundar S, Chakravarty J, Singh J, Verma D, Agrawal N, Dinkar A. Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India. Am J Trop Med Hyg. 2024 Jun 4:tpmd230738. doi: 10.4269/ajtmh.23-0738. Online ahead of print. PMID: 38834057
6. Palić S, Chu WY, Sundar S, Mondal D, Das P, Pandey K, Raja S, Rijal S, Roseboom IC, Hamadeh A, Malik PRV, Beijnen JH, Huitema ADR, Sjögren E, Alves F, Dorlo TPC. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. J Antimicrob Chemother. 2024 Jul 1;79(7):1547-1554. doi: 10.1093/jac/dkac129. PMID: 38727613.
7. Ng SS, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, Kuns R, Chauhan SB, Hou J, Li XY, Frame TCM, McEnroe BA, Moore E, Na J, Engel JA, Soon MSF, Singh B, Kueh AJ, Herold MJ, Montes de Oca M, Singh SS, Bunn PT, Aguilera AR, Casey M, Braun M, Ghazanfari N, Wani S, Wang Y, Amante FH, Edwards CL, Haque A, Dougall WC, Singh OP, Baxter AG, Teng MWL, Loukas A, Daly NL, Cloonan N, Degli-Esposti MA, Uzonna J, Heath WR, Bald T, Tey SK, Nakamura K, Hill GR, Kumar R, Sundar S, Smyth MJ, Engwerda CR. Author Correction: The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.

Nat Immunol. 2024 Apr;25(4):716. doi: 10.1038/s41590-024-01770-8. Erratum for:
Nat Immunol. 2020 Oct;21(10):1205-1218. doi: 10.1038/s41590-020-0758-6. PMID:
38360937.

8. Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R, Kumar A, et al. (2024) A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. *PLoS Negl Trop Dis* 18(6): e0012242. <https://doi.org/10.1371/journal.pntd.0012242>
9. Singh OP, Chaubey R, Kushwaha AK, Fay MP, Sacks D, Sundar S. Visceral **Leishmaniasis**-Human Immunodeficiency Virus-Coinfected Patients Are Highly Infectious to Sandflies in an Endemic Area in India. *J Infect Dis*. 2024 Jun 14;229(6):1909-1912. doi: 10.1093/infdis/jiae156. PMID: 38713583
10. Kausar G, Chauhan SB, Roy R, Kumar S, Engwerda C, Nylen S, Kumar R, Wilson ME, Sundar S. Apolipoprotein E Is Upregulated in Blood and Circulating Monocytes of Indian Patients With Visceral **Leishmaniasis**. *Parasite Immunol*. 2024 May;46(5):e13036. doi: 10.1111/pim.13036. PMID: 38720445
11. Ng SS, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, Kuns R, Chauhan SB, Hou J, Li XY, Frame TCM, McEnroe BA, Moore E, Na J, Engel JA, Soon MSF, Singh B, Kueh AJ, Herold MJ, Montes de Oca M, Singh SS, Bunn PT, Aguilera AR, Casey M, Braun M, Ghazanfari N, Wani S, Wang Y, Amante FH, Edwards CL, Haque A, Dougall WC, Singh OP, Baxter AG, Teng MWL, Loukas A, Daly NL, Cloonan N, Degli-Esposti MA, Uzonna J, Heath WR, Bald T, Tey SK, Nakamura K, Hill GR, Kumar R, Sundar S, Smyth MJ, Engwerda CR. Author Correction: The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. *Nat Immunol*. 2024 Apr;25(4):716. doi: 10.1038/s41590-024-01770-8. Erratum for: *Nat Immunol*. 2020 Oct;21(10):1205-1218. doi: 10.1038/s41590-020-0758-6. PMID: 38360937.
12. Sundar S, Jitendra Singh, Vishal Kumar Singh, Neha Agrawal & Rajiv Kumar (2024) Current and emerging therapies for the treatment of leishmaniasis, *Expert Opinion on Orphan Drugs*, 12:1, 19-32, DOI: 10.1080/21678707.2024.2335248
13. Kausar G, Chauhan SB, Roy R, Verma V, Pandey S, Niyaz A, Chakravarty J, Engwerda CR, Nylen S, Kumar R, Wilson ME, Sundar S. Phenotypic and functional characteristics of monocyte subsets in the blood and bone marrow of Indian subjects with Visceral **Leishmaniasis**. *PLoS Negl Trop Dis*. 2024 Apr 26;18(4):e0012112. doi: 10.1371/journal.pntd.0012112. Online ahead of print. PMID: 38669292
14. Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed R, Naylor C, Maguire BJ, Siddiqui NA, Harriss E, Rahi M, Alves F, Sundar S, Stepniewska K, Musa A, Guerin PJ, Pandey K. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and

- observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform. *PLoS Negl Trop Dis*. 2024 Apr 16;18(4):e0011635. doi: 10.1371/journal.pntd.0011635.
15. Arora K, Dhruw B, Pm S, Madhukar P, Sundar S, Mudavath SL. Dual Drug Delivery for Augmenting Bacterial Wound Complications via Tailored Ultradeflexible Carriers. *Bioconjug Chem*. 2024 Jun 19;35(6):766-779. doi: 10.1021/acs.bioconjchem.4c00102. Epub 2024 Apr 16. PMID: 38625106.
 16. Chhajed R, Dahal P, Singh-Phulgenda S, Brack M, Naylor C, Sundar S, Alves F, Stepniewska K, Guerin PJ. Estimating the proportion of relapse following treatment of Visceral **Leishmaniasis**: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review. *Lancet Reg Health Southeast Asia*. 2023 Dec 6;22:100317. doi: 10.1016/j.lansea.2023.100317. eCollection 2024 Mar. PMID: 38482151
 17. Kumar S, Chauhan SB, Upadhyay S, Singh SS, Verma V, Kumar R, Engwerda C, Nylén S, Sundar S. Altered IL-7 signaling in CD4+ T cells from patients with visceral **leishmaniasis**. *PLoS Negl Trop Dis*. 2024 Feb 26;18(2):e0011960. doi: 10.1371/journal.pntd.0011960. Online ahead of print. PMID: 38408097
 18. Singh AK, de Gooyer T, Singh OP, Pandey S, Neyaz A, Cloots K, Kansal S, Malaviya P, Rai M, Nylén S, Chakravarty J, Hasker E, **Sundar S**. *Wuchereria bancrofti* infection is associated with progression to clinical visceral leishmaniasis in VL- endemic areas in Muzaffarpur, Bihar, India. *PLoS Negl Trop Dis*. 2023 Oct 30;17(10):e0011729. doi: 10.1371/journal.pntd.0011729. eCollection 2023 Oct. PMID: 37903175
 19. Edwards CL, Engel JA, de Labastida Rivera F, Ng SS, Corvino D, Montes de Oca M, Frame TC, Chauhan SB, Singh SS, Kumar A, Wang Y, Na J, Mukhopadhyay P, Lee JS, Nylén S, **Sundar S**, Kumar R, Engwerda CR. A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases. *JCI Insight*. 2023 Dec 22;8(24):e169362. doi: 10.1172/jci.insight.169362. PMID: 37917177
 20. Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA, Naylor C, Wilson J, Buck G, Rahi M, Alves F, Malaviya P, **Sundar S**, Ritmeijer K, Stepniewska K, Pandey K, Guérin PJ, Musa A. Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis. *BMJ Open*. 2023 Dec 14;13(12):e074841. doi: 10.1136/bmjopen-2023-074841. PMID: 38101841
 21. Tiwari R, Gupta RP, Singh VK, Kumar A, Rajneesh, Madhukar P, **Sundar S**, Gautam V, Kumar R. Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment. *ACS Omega*. 2023 Nov 1;8(45):42014-42027. doi: 10.1021/acsomega.3c04587. eCollection 2023 Nov 14. PMID: 38024747

22. Singh AK, de Gooyer T, Singh OP, Pandey S, Neyaz A, Cloots K, Kansal S, Malaviya P, Rai M, Nylén S, Chakravarty J, Hasker E, **Sundar S**. Wuchereriabancrofti infection is associated with progression to clinical visceral leishmaniasis in VL- endemic areas in Muzaffarpur, Bihar, India. PLoSNegl Trop Dis. 2023 Oct 30;17(10):e0011729. doi: 10.1371/journal.pntd.0011729. eCollection 2023 Oct.PMID: 37903175
23. Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A, Naylor C, Wilson J, Buck G, Rahi M, Malaviya P, Alves F, **Sundar S**, Ritmeijer K, Stepniewska K, Guérin PJ, Pandey K ,Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis. BMJ Open. 2023 Oct 28;13(10):e074679. doi: 10.1136/bmjopen-2023-074679.PMID: 37898487
24. Pierneef L, Malaviya P, van Hooij A, **Sundar S**, Singh AK, Kumar R, de Jong D, Meuldijk M, Kumar A, Zhou Z, Cloots K, Corstjens P, Hasker E, Geluk A. Field-friendly anti-PGL-I serosurvey in children to monitor *Mycobacterium leprae* transmission in Bihar, India. Front Med (Lausanne). 2023 Sep 27;10:1260375. doi: 10.3389/fmed.2023.1260375. eCollection 2023.PMID: 37828950
25. Chakravarty J, Reddy S, Gupta MK, Tilak R, Diwaker C, Sundar S. Screening for cryptococcal antigen in asymptomatic PLHIV: an urgent need in Eastern India. AIDS. 2023 Aug 25. doi: 10.1097/QAD.0000000000003702. Epub ahead of print. PMID: 37650766.
26. Kumar A, Singh VK, Tiwari R, Madhukar P, Rajneesh, Kumar S, Gautam V, Engwerda C, Sundar S, Kumar R. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination. Front Immunol. 2023 Aug 11;14:1236952. doi: 10.3389/fimmu.2023.1236952. PMID: 37638047; PMCID: PMC10451093.
27. Sundar S, Singh J, Dinkar A, Agrawal N. Safety and Effectiveness of Miltefosine in Post-Kala-Azar Dermal Leishmaniasis: An Observational Study. Open Forum Infect Dis. 2023 May 2;10(5):ofad231. doi: 10.1093/ofid/ofad231. eCollection 2023 May.PMID: 37234513
28. Chaubey R, Shukla A, Kushwaha AK, Tiwary P, Kumar Singh S, Hennings S, Singh OP, Lawyer P, Rowton E, Petersen CA, Bernhardt SA, **Sundar S**. Assessing insecticide susceptibility, diagnostic dose and time for the sand fly *Phlebotomus argentipes*, the vector of visceral **leishmaniasis** in India, using the CDC bottle bioassay. PLoSNegl Trop Dis. 2023 May 10;17(5):e0011276. doi: 10.1371/journal.pntd.0011276. eCollection 2023 May.PMID: 37163529
29. Kushwaha AK, Shukla A, Scorza BM, Kumari Rai T, Chaubey R, Kumar Maurya D, Srivastva S, Upadhyay S, Kumar Singh A, Malviya P, Singh OP, Kumar Scholar V, Tiwary P, Singh SK, Lawyer P, Rowton E, Bernhardt SA, Petersen CA, **Sundar S**. Livestock and rodents within an endemic focus of Visceral Leishmaniasis are not

reservoir hosts for *Leishmania donovani*. PLoS Negl Trop Dis. 2022 Oct 20;16(10):e0010347.

30. Singh OP, **Sundar S**. Visceral leishmaniasis elimination in India: progress and the road ahead. *Expert Rev Anti Infect Ther*. 2022 Sep 25;1-8. doi: 10.1080/14787210.2022.2126352. Online ahead of print. PMID: 36111688
31. Roseboom IC, Thijssen B, Rosing H, Alves F, Sundar S, Beijnen JH, Dorlo TPC. Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2022 Aug 15;1206:123354. doi: 10.1016/j.jchromb.2022.123354. Epub 2022 Jul 4. PMID: 35810536
32. Singh SS, Chauhan SB, Ng SS, Corvino D, de Labastida Rivera F, Engel JA, Waddell N, Mukhopadhyay P, Johnston RL, Koufariotis LT, Nysten S, Prakash Singh O, Engwerda CR, Kumar R, Sundar S. Increased amphiregulin expression by CD4⁺ T cells from individuals with asymptomatic *Leishmania donovani* infection. *Clin Transl Immunology*. 2022 May 27;11(6):e1396. doi: 10.1002/cti2.1396. eCollection 2022. PMID: 35663920
33. Pandey RK, Ojha R, Devender M, Sebastian P, Namdeo M, Kumbhar BV, **Sundar S**, Maurya R, Prajapati VK. Febrifugine dihydrochloride as a new oral chemotherapeutic agent against visceral leishmaniasis infection. *Exp Parasitol*. 2022 Apr 4;236-237:108250. doi: 10.1016/j.exppara.2022.108250. Online ahead of print. PMID: 35390313
34. Cloots K, Singh OP, Singh AK, Kushwaha AK, Malaviya P, Kansal S, Hasker E, **Sundar S**. Diagnosis of Visceral Leishmaniasis in an Elimination Setting: A Validation Study of the Diagnostic Algorithm in India. *Diagnostics (Basel)*. 2022 Mar 9;12(3):670. doi: 10.3390/diagnostics12030670. PMID: 35328223
35. Kumar A, Singh B, Tiwari R, Singh VK, Singh SS, **Sundar S**, Kumar R. Emerging role of $\gamma\delta$ T cells in protozoan infection and their potential clinical application. *Infect Genet Evol*. 2022 Mar;98:105210. doi: 10.1016/j.meegid.2022.105210. Epub 2022 Jan 12. PMID: 35031509
36. Routaray CB, Kumar A, **Sundar S**, Sathe G, Pawar H, Pai K. An In-depth Proteomic Map of *Leishmania donovani* Isolates from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient. *Acta Parasitol*. 2022 Jun;67(2):687-696. doi: 10.1007/s11686-021-00511-3. Epub 2022 Jan 12. PMID: 35020128
37. Thakur L, Madaan P, Jain A, Shankar V, Negi A, Chauhan SB, **Sundar S**, Singh OP, Jain M. An Insight Into Systemic Immune Response in *Leishmania donovani* Mediated Atypical Cutaneous **Leishmaniasis** in the New Endemic State of

38. Ghosh S, Biswas S, Mukherjee S, Pal A, Saxena A, **Sundar S**, Dujardin JC, Das S, Roy S, Mukhopadhyay R, Mukherjee B A Novel Bioimpedance-Based Detection of Miltefosine Susceptibility Among Clinical *Leishmania donovani* Isolates of the Indian Subcontinent Exhibiting Resistance to Multiple Drugs.Front Cell Infect Microbiol. 2021 Nov 29;11:768830. doi: 10.3389/fcimb.2021.768830. eCollection 2021.PMID: 34912730
39. Singh SS, Chauhan SB, Kumar A, Kumar S, Engwerda CR, **Sundar S**, Kumar R.Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target..J Cell Physiol. 2021 Oct 26. doi: 10.1002/jcp.30615. PMID: 34698381
40. Verrest L, Wasunna M, Kokwaro G, Aman R, Musa AM, Khalil EAG, Mudawi M, Younis BM, Hailu A, Hurissa Z, Hailu W, Tesfaye S, Makonnen E, Mekonnen Y, Huitema ADR, Beijnen JH, Kshirsagar SA, Chakravarty J, Rai M, **Sundar S**, Alves F, DorloTPC.Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral **Leishmaniasis** Patients. Clin Pharmacokinet. 2021 Jun 9. doi: 10.1007/s40262-021-01036-8. Online ahead of print.PMID: 34105063
41. Parvez S, Yadagiri G, Arora K, Javaid A, Kushwaha AK, Singh OP, Sundar S, Mudavath SL Coalition of Biological Agent (Melatonin) With Chemotherapeutic Agent (Amphotericin B) for Combating Visceral **Leishmaniasis** via Oral Administration of Modified Solid Lipid Nanoparticles.ACS Biomater Sci Eng. 2021 Aug 31. doi: 10.1021/acsbiomaterials.1c00859. Online ahead of print.PMID: 34463477
42. Dixit KK, Ramesh V, Upadhyay S, Singh AK, Singh OP, **Sundar S**, Singh R, Salotra P. Utility of Blood as the Clinical Specimen for the Molecular Diagnosis of Post-Kala-Azar Dermal Leishmaniasis.J Clin Microbiol. 2021 Aug 18;59(9):e0013221. doi: 10.1128/JCM.00132-21. Epub 2021 Aug 18.PMID: 34160275
43. Cloots K, Singh OP, Singh AK, Van der Auwera G, Kumar P, Gedda MR, Rai TK, Hasker E, **Sundar S**, BoelaertM.Assessing *L. donovani* Skin Parasite Load: A Proof of Concept Study of a Microbiopsy Device in an Indian Setting. Front Cell Infect Microbiol. 2021 Mar 11;11:645121. doi: 10.3389/fcimb.2021.645121. eCollection 2021.PMID: 33791246
44. Kushwaha AK, Scorza BM, Singh OP, Rowton E, Lawyer P, **Sundar S**, Petersen CA. Domestic Mammals as Reservoirs for *Leishmania donovani* on the Indian Subcontinent: Possibility and Consequences on Elimination.TransboundEmerg Dis. 2021 Mar 8. doi: 10.1111/tbed.14061. Online ahead of print.PMID: 33686764

45. Kupani M, Sharma S, Pandey RK, Kumar R, **Sundar S**, Mehrotra S. IL-10 and TGF- β Induced Arginase Expression Contributes to Deficient Nitric Oxide Response in Human Visceral Leishmaniasis. *Front Cell Infect Microbiol*. 2021 Feb 18;10:614165. doi: 10.3389/fcimb.2020.614165. eCollection 2020. PMID: 33680983
46. Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, Rowton E, Chaubey R, Singh AK, Rai TK, Fay MP, Chakravarty J, Sacks D, **Sundar S**. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. *Lancet Microbe*. 2021 Jan;2(1):e23-e31. doi: 10.1016/S2666-5247(20)30166-X. PMID: 33615281
47. Yadav S, Prakash J, Singh OP, Gedda MR, Chauhan SB, **Sundar S**, Dubey VK. IFN- γ ⁺ CD4⁺T cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of *Leishmania donovani* against visceral leishmaniasis. *Cell Immunol*. 2021 Mar;361:104272. doi: 10.1016/j.cellimm.2020.104272. Epub 2020 Dec 21. PMID: 33445051
48. Routaray CB, Bhor R, Bai S, Kadam NS, Jagtap S, Doshi PJ, **Sundar S**, Sawant S, Kulkarni MJ, Pai K. SWATH-MS based quantitative proteomics analysis to evaluate the antileishmanial effect of Commiphora wightii- Guggul and amphotericin B on a clinical isolate of *Leishmania donovani*. *J Proteomics*. 2021 Feb 10;232:104017. doi: 10.1016/j.jprot.2020.104017. Epub 2020 Nov 5. PMID: 33160910
49. Gedda MR, Madhukar P, Shukla A, Mudavath SL, Srivastava ON, Singh OP, **Sundar S**. Nanodiagnosics in leishmaniasis: A new frontiers for early elimination. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2021 March:e1675. doi: 10.1002/wnan.1675. Online ahead of print. PMID: 33142369
50. Parvez S, Yadagiri G, Karole A, Singh OP, Verma A, **Sundar S**, Mudavath SL. Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity. *Front Cell Infect Microbiol*. 2020 Oct 15;10:570573. doi: 10.3389/fcimb.2020.570573. eCollection 2020. PMID: 33178626
51. Mukherjee S, Pradhan S, Ghosh S, **Sundar S**, Das S, Mukherjee B, Roy S. Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant *Leishmania donovani* With Increased Efficacy. *Front Cell Infect Microbiol*. 2020 Nov 10;10:595415. doi: 10.3389/fcimb.2020.595415. eCollection 2020. PMID: 33240825
52. Parvez S, Yadagiri G, Singh A, Karole A, Singh OP, **Sundar S**, Mudavath SL. Improving anti-leishmanial activity of Amphotericin B and Paromomycin using co-delivery in D- α -tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored Nano-lipid carrier system. *Chem Phys Lipids*. 2020 Jul 1:104946. doi: 10.1016/j.chemphyslip.2020.104946. Online ahead of print. PMID: 32621810

53. Saha B, Pai K, **Sundar S**, Bhattacharyya M, Bodhale NP. The drug resistance mechanisms in *Leishmania donovani* are independent of immunosuppression. *Cytokine*. 2021 Sep 22;155300. doi: 10.1016/j.cyto.2020.155300. Online ahead of print.PMID: 32978033
54. Marlais T, Bhattacharyya T, Pearson C, Gardner BL, Marhoon S, Airs S, Hayes K, Falconar AK, Singh OP, Reed SG, El-Safi S, **Sundar S**, Miles MA. Isolation and characterisation of *Leishmania donovani* protein antigens from urine of visceral leishmaniasis patients. *PLoS One*. 2020 Sep 14;15(9):e0238840. doi: 10.1371/journal.pone.0238840. eCollection 2020.PMID: 32925980
55. Singh A, Yadagiri G, Parvez S, Singh OP, Verma A, **Sundar S**, Mudavath SL. Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B₁₂-stearic acid conjugate. *Mater Sci Eng C Mater Biol Appl*. 2020 Dec;117:111279. doi: 10.1016/j.msec.2020.111279. Epub 2020 Jul 9.PMID: 32919641
56. Potvin JE, Leprohon P, Queffeuilou M, **Sundar S**, Ouellette M. Mutations in an aquaglyceroporin as a proven marker of antimony clinical resistance in the parasite *Leishmania donovani*. *Clin Infect Dis*. 2020 Aug 22:ciaa1236. doi: 10.1093/cid/ciaa1236. Online ahead of print.PMID: 32827255
57. Singh OP, Hasker E, Boelaert M, Sacks D, **Sundar S**. Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination. *PLoS Negl Trop Dis*. 2020 Aug 13;14(8):e0008363. doi: 10.1371/journal.pntd.0008363. eCollection 2020 Aug.PMID: 32790716
58. Gedda MR, Madhukar P, Vishwakarma AK, Verma V, Kushwaha AK, Yadagiri G, Mudavath SL, Singh OP, Srivastava ON, **Sundar S**. Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An *in vitro* and Preclinical Study. *Front Chem*. 2020 Jul 3;8:510. doi: 10.3389/fchem.2020.00510. eCollection 2020.PMID: 32719770
59. Parvez S, Yadagiri G, Gedda MR, Singh A, Singh OP, Verma A, **Sundar S**, Mudavath SL. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. *Sci Rep*. 2020 Jul 22;10(1):12243. doi: 10.1038/s41598-020-69276-5.PMID: 32699361
60. Aakriti Singh‡, Sandeep Sharma‡, Ganesh Yadagiri, Shabi Parvez, Nikhil Koratkar, Om Prakash Singh, Shyam Sundar, Vijayakumar Shanmugam and Shyam Lal Mudavath, Sensible graphene oxide differentiates macrophages and *Leishmania*: A Bio-nano interplay in attenuating intracellular parasite: (2020) *RSC Advances*, 10: 27502–27511. DOI: [DOI: 10.1039/d0ra04266h](https://doi.org/10.1039/d0ra04266h).

61. Gedda MR, Singh B, Kumar D, Singh AK, Madhukar P, Upadhyay S, Singh OP, **Sundar S**. Post kala-azar dermal leishmaniasis: A threat to elimination program. *PLoS Negl Trop Dis*. 2020 Jul 2;14(7):e0008221. doi: 10.1371/journal.pntd.0008221. eCollection 2020 Jul. PMID: 32614818
62. Singh OP, Syn G, Nylén S, Engwerda C, Sacks D, Wilson ME, Kumar R, Chakravarty J, **Sundar S**, Blackwell JM, Fakiola M. Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients. *J Infect Dis*. 2020 Jul 2;:jiaa381. doi: 10.1093/infdis/jiaa381. Online ahead of print. PMID: 32614452
63. Kumar R, Bunn PT, Singh SS, Ng SS, Montes de Oca M, De Labastida Rivera F, Chauhan SB, Singh N, Faleiro RJ, Edwards CL, Frame TCM, Sheel M, Austin RJ, Lane SW, Bald T, Smyth MJ, Hill GR, Best SE, Haque A, Corvino D, Waddell N, Koufariotis L, Mukhopadhyay P, Rai M, Chakravarty J, Singh OP, Sacks D, Nylén S, Uzonna J, **Sundar S**, Engwerda CR. Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. *Cell Rep*. 2020 Feb 25;30(8):2512-2525.e9. doi: 10.1016/j.celrep.2020.01.099. PMID: 32101732
64. Goswami A, Mukherjee K, Mazumder A, Ganguly S, Mukherjee I, Chakrabarti S, Roy S, **Sundar S**, Chattopadhyay K, Bhattacharyya SN. MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages. *EMBO Mol Med*. 2020 Mar 6;12(3):e11011. doi: 10.15252/emmm.201911011. Epub 2020 Feb 7. PMID: 32031337
65. Cloots K, Burza S, Malaviya P, Hasker E, Kansal S, Mollett G, Chakravarty J, Roy N, Lal BK, Rijal S, **Sundar S**, Boelaert M. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. *PLoS Negl Trop Dis*. 2020 Jan 29;14(1):e0007995. doi: 10.1371/journal.pntd.0007995. eCollection 2020 Jan. PMID: 31995564
66. De Rycker M, Horn D, Aldridge B, Amewu RK, Barry CE 3rd, Buckner FS, Cook S, Ferguson MAJ, Gobeau N, Herrmann J, Herrling P, Hope W, Keiser J, Lafuente-Monasterio MJ, Leeson PD, Leroy D, Manjunatha UH, McCarthy J, Miles TJ, Mizrahi V, Moshynets O, Niles J, Overington JP, Pottage J, Rao SPS, Read KD, Ribeiro I, Silver LL, Southern J, Spangenberg T, **Sundar S**, Taylor C, Van Voorhis W, White NJ, Wyllie S, Wyatt PG, Gilbert IH. Setting Our Sights on Infectious Diseases. *ACS Infect Dis*. 2020 Jan 10;6(1):3-13. doi:10.1021/acsinfecdis.9b00371. Epub 2019 Dec 6. PMID: 31808676

67. Hasker E, Malaviya P, Scholar VK, de Koning P, Singh OP, Kansal S, Cloots K, Boelaert M, **Sundar S**. Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site. *PLoS Negl Trop Dis*. 2019 Oct 25;13(10):e0007798. doi: 10.1371/journal.pntd.0007798. eCollection 2019 Oct. PMID:31652262
68. Prakash J, Iqbal M, Patel PS, Prakash **S**, **Sundar S**, Singh U. Outcome of HIV Related Kidney Diseases Treated with Combined Antiretroviral Therapy (cART). *J Assoc Physicians India*. 2019 Sep;67(9):18-22. PMID: 31561682
69. Singh B, Bhushan Chauhan S, Kumar R, Singh SS, Ng S, Amante F, de Labastida Rivera F, Singh OP, Rai M, Nylén **S**, **Sundar S**, Engwerda C. A molecular signature for CD8+ T cells from visceral leishmaniasis patients. *Parasite Immunol*. 2019 Nov;41(11):e12669. doi: 10.1111/pim.12669. Epub 2019 Sep 30. PMID:31494954
70. Lappan R, Classon C, Kumar S, Singh OP, de Almeida RV, Chakravarty J, Kumari P, Kansal **S**, **Sundar S**, Blackwell JM. Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. *PLoS Negl Trop Dis*. 2019 Sep 6;13(9):e0007444. doi: 10.1371/journal.pntd.0007444. eCollection 2019 Sep. PMID:31490933
71. **Sundar S**, Singh A, Agrawal N, Chakravarty J. Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. *Am J Trop Med Hyg*. 2019 Oct;101(4):795-798. doi: 10.4269/ajtmh.19-0179. PMID:31436156
72. Fakiola M, Singh OP, Syn G, Singh T, Singh B, Chakravarty J, **Sundar S**, Blackwell JM. Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. *PLoS Negl Trop Dis*. 2019 Aug 16;13(8):e0007673. doi: 10.1371/journal.pntd.0007673. eCollection 2019 Aug. PMID:31419223
73. Singh OP, Gedda MR, Mudavath SL, Srivastava ON, **Sundar S**. Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. *Nanomedicine (Lond)*. 2019 Jul;14(14):1911-1927. doi: 10.2217/nmm-2018-0448. Epub 2019 Jul 17. PMID:31313971
a.
74. **Sundar S**, Agrawal N, Singh B. Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. *Expert Opin Drug Metab Toxicol*. 2019 Jul;15(7):595-612. doi: 10.1080/17425255.2019.1629417. Epub 2019 Jun 17. PMID:31174439
75. Veronica J, Chandrasekaran S, Dayakar A, Devender M, Prajapati VK, **Sundar S**, Maurya R. Iron superoxide dismutase contributes to miltefosine resistance in

- Leishmania donovani*. FEBS J. 2019 May 13. doi: 10.1111/febs.14923. PMID: 31087522
76. Chakravarty J, **Sundar S**. Current and emerging medications for the treatment of leishmaniasis. *Expert OpinPharmacother*. 2019 May 7:1-15. doi: 10.1080/14656566.2019.1609940. PMID: 31063412
77. Bremer Hinckel BC, Marlais T, Airs S, Bhattacharyya T, Imamura H, Dujardin JC, El-Safi S, Singh OP, **Sundar S**, Falconar AK, Andersson B, Litvinov S, Miles MA, Mertens P. Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis. *PLoSNegl Trop Dis*. 2019 May 6;13(5):e0007353. doi: 10.1371/journal.pntd.0007353. eCollection 2019 May. PMID: 31059497
78. Gautam A, Gedda MR, Rai M, **Sundar S**, Chakravarty J. Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach.*Curr Mol Med*. 2019 Apr 5. doi: 10.2174/1566524019666190405120441. PMID: 30950352
79. Chakravarty J, Hasker E, Kansal S, Singh OP, Malaviya P, Singh AK, Chourasia A, Singh T, Sudarshan M, Singh AP, Singh B, Singh RP, Ostyn B, Fakiola M, Picado A, Menten J, Blackwell JM, Wilson ME, Sacks D, Boelaert M, **Sundar S**. Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. *PLoSNegl Trop Dis*. 2019 Mar 27;13(3):e0007216. doi: 10.1371/journal.pntd.0007216. eCollection 2019 Mar. PMID: 30917114
80. Joshi S, Yadav NK, Rawat K, Kumar V, Ali R, Sahasrabuddhe AA, Siddiqi MI, Haq W, **Sundar S**, Dube A. Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of *Leishmania (Leishmania) donovani*.*Front Immunol*. 2019 Feb 28;10:288. doi: 10.3389/fimmu.2019.00288. eCollection 2019. PMID:30873164
81. Chauhan SB, Faleiro R, Kumar R, Ng S, Singh B, Singh OP, Singh SS, Amante F, Rivera FL, Rai M, Chakravarty J, Sacks D, Nylen **S, Sundar S**, Engwerda C. IL-2 is an upstream regulator of CD4+ T cells from visceral leishmaniasis patients with therapeutic potential. *J Infect Dis*. 2019 Feb 23. pii: jiz074. doi: 10.1093/infdis/jiz074. [Epub ahead of print] PMID: 30796820
82. Singh B, Singh OP, Singh N, Singh SS, **Sundar S**. Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis. *Am J Trop Med Hyg*. 2019 Feb 18. doi: 10.4269/ajtmh.18-0350. PMID: 30793688
83. Abeijon C, Alves F, Monnerat S, Wasunna M, Mbui J, Viana AG, Bueno LL, Siqueira WF, Carvalho SG, Agrawal N, Fujiwara R, **Sundar S**, Campos-Neto A. Development of a multiplexed assay for the detection of *Leishmania donovani/Leishmania infantum* protein biomarkers in the urine of patients with

- visceral leishmaniasis. *J Clin Microbiol*. 2019 Feb 20. pii: JCM.02076-18. doi: 10.1128/JCM.02076-18. PMID: 30787142
- 84.** Rijal **S**, **Sundar S**, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: the road ahead. *BMJ*. 2019 Jan 22;364:k5224. doi: 10.1136/bmj.k5224. PMID: 30670453
- 85.** Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Gupta R, Negi NS, Das P, **Sundar S**, Singh R, Salotra P. Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL). *PLoS Negl Trop Dis*. 2018 Nov 15;12(11):e0006922. doi: 10.1371/journal.pntd.0006922. PMID: 30439953
- 86.** Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gillemans Q, Thunissen C, Hinckel BCB, Pearson C, Gardner BL, Airs S, de la Roche M, Hayes K, Hafezi H, Falconar AK, Eisa O, Saad A, Khanal B, Bhattarai NR, Rijal S, Boelaert M, El-Safi **S**, **Sundar S**, Miles MA. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis. *Front Cell Infect Microbiol*. 2018 Dec 13;8:427. doi: 10.3389/fcimb.2018.00427. eCollection 2018. PMID: 30619774
- 87.** Gautam A, Chakravarty J, Singh VK, Ghosh A, Chauhan SB, Rai M, **Sundar S**. Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. *BMC Infect Dis*. 2018 Dec 27;18(1):692. doi: 10.1186/s12879-018-3618-3. PMID: 30587145
- 88.** Saha G, Khamar BM, Singh OP, **Sundar S**, Dubey VK. *Leishmania donovani* evades Caspase 1 dependent host defense mechanism during infection. *Int J Biol Macromol*. 2018 Dec 22. pii: S0141-8130(18)36295-0. doi: 10.1016/j.ijbiomac.2018.12.185. PMID: 30584943
- 89.** Mollett G, Bremer Hinckel BC, Bhattacharyya T, Marlais T, Singh OP, Mertens P, Falconar AK, El-Safi **S**, **Sundar S**, Miles MA. Detection of IgG1 against rK39 improves monitoring of treatment outcome in visceral leishmaniasis. *Clin Infect Dis*. 2018 Dec 12. doi: 10.1093/cid/ciy1062 PMID: 30541022
- 90.** Bulstra CA, Le Rutte EA, Malaviya P, Hasker EC, Coffeng LE, Picado A, Singh OP, Boelaert MC, de Vlas SJ, **Sundar S**. Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India. *PLoS Negl Trop Dis*. 2018 Dec 6;12(12):e0006888. doi: 10.1371/journal.pntd.0006888. eCollection 2018 Dec. PMID: 30521529
- 91.** Singh B, Fakiola M, Sudarshan M, Oommen J, Singh SS, **Sundar S**, Blackwell JM. HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-

- DRB1 as a genetic risk factor for visceral leishmaniasis. *Immunology*. 2018 Nov 7. doi: 10.1111/imm.13018. PMID:30403401
92. Singh B, Singh SS, **Sundar S**. Hepcidin mediated iron homeostasis as immune regulator in visceral leishmaniasis patients. *Parasite Immunol*. 2018 Nov 6:e12601. doi: 10.1111/pim.12601. PMID: 30402883
93. Hasker E, Malaviya P, Cloots K, Picado A, Singh OP, Kansal S, Boelaert M, **Sundar S**. Visceral Leishmaniasis in the Muzaffapur Demographic Surveillance Site: A Spatiotemporal Analysis. *Am J Trop Med Hyg*. 2018 Oct 8. doi: 10.4269/ajtmh.18-0448. PMID: 30298812
94. **Sundar S**, Singh OP, Chakravarty J. Visceral Leishmaniasis elimination targets in India, strategies for preventing resurgence. *Expert Rev Anti Infect Ther*. 2018 Oct 5. doi: 10.1080/14787210.2018.1532790. PMID: 30289007
95. Singh N, Sundar S. Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. *PLoS One*. 13(6):e0199817, 2018. PMID:29953494
96. Singh N, Kumar R, Chauhan SB, Engwerda C, **Sundar S**. Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis. *J Infect Dis*. 2018 Jul 19. doi: 10.1093/infdis/jiy228. PMID: 30053070
97. Sundar S, Singh OP. Molecular Diagnosis of Visceral Leishmaniasis. *Mol Diagn Ther*. 2018. PMID: 29922885
98. Sundar S, Singh B. Emerging therapeutic targets for treatment of leishmaniasis. *Expert Opin Ther Targets*. 22(6):467-486, 2018. PMID: 29718739
99. Sundar S, Singh B. Understanding Leishmania parasites through proteomics and implications for the clinic. *Expert Rev Proteomics*. 15(5):371-390, 2018. PMID: 29717934
100. Singh T, Fakiola M, Oommen J, Singh AP, Singh AK, Smith N, Chakravarty J, Sundar S, Blackwell JM. Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. *J Immunol*. 15;200(8):2727-2737, 2018 PMID: 29507109
101. Chaubey P, Mishra B, Mudavath SL, Patel RR, Chaurasia S, Sundar S, Suvarna V, Monteiro M. Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against *Leishmania donovani*. *Int J Biol Macromol*. 4;111:109-120, 2018. PMID: 29307805

- 102.** Sundar S, Agarwal D. Visceral Leishmaniasis – Optimum Treatment Options in Children. *Pediatr Infect Dis J.* 37(5):492-494, 2017 .PMID: 29280784
- 103.** Tiwary P, Kumar D, Sundar S. Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis. *Am J Trop Med Hyg.* 98(2):492-496, 2017 .PMID: 29280431
- 104.** Sundar S, Singh A. Chemotherapeutics of visceral leishmaniasis: present and future developments. *Parasitology.* 145(4):481-489, 2017.PMID: 29215329
- 105.** Kumar R, Chauhan SB, Ng SS, Sundar S, Engwerda CR. Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. *Front Immunol.* 8;8:1492, 2017. PMID: 29167671
- 106.** Das S, Giri S, Sundar S, Shaha C. Leishmania donovani Tryparedoxin Peroxidases: functional involvement during infection and drug treatment. *Antimicrob Agents Chemother.* 21;62(1). pii: e00806-17, 2017 PMID: 29061756
- 107.** Verma A, Bhandari V, Deep DK, Sundar S, Dujardin JC, Singh R, Salotra P. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani. *Int J Parasitol Drugs Drug Resist.* 10;7(3):370-377, 2017. PMID:29035735
- 108.** Prakash J, Ganiger V, Prakash S, Sivasankar M, Sundar S, Singh U. Kidney Disease in Human Immunodeficiency Virus-seropositive Patients: Absence of Human Immunodeficiency Virus-associated Nephropathy was a Characteristic Feature. *Indian J Nephrol.* 2017; 27:271-276. doi: 10.4103/0971-4065.202400.PMID:28761228
- 109.** Sukla S, Roy S, Sundar S, Biswas S. Leptomonas seymourinarna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India. *Arch Virol.* 162(12):3827-3835 , 2017.PMID:28939968
- 110.** Sharma S, Srivastva S, Davis RE, Singh SS, Kumar R, Nylén S, Wilson ME, Sundar S. The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis. *Am J Trop Med* 97(3):767-770, 2017. PMID: 28820688
- 111.** Tandon R, Chandra S, Baharia RK, Misra P, DAS S, Rawat K, Siddiqi MI, Sundar S, Dube A. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate. *Parasitology.* 145(4):508-526, 2017. PMID: 28691653
- 112.** Chakraborty A, Kurati SP, Mahata SK, Sundar S, Roy S, Sen M. Wnt5a Signaling Promotes Host Defense against Leishmania donovani Infection. *J Immunol.* 199(3):992-1002, 2017.PMID: 28659356

- 113.** Kansal S, Chakravarty J, Kumar A, Malaviya P, Boelaert M, Hasker E, Ostyn B, Sundar S. Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India. *Trop Med Int Health.* 22(8):1037-1042, 2017. PMID: 28594453
- 114.** Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, Sundar S, Ramesh V, Dujardin JC, Salotra P. Increased miltefosine tolerance in clinical isolates of *Leishmania donovani* is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. *PLoS Negl Trop Dis.* 11(6):e0005641, 2017. PMID: 28575060
- 115.** Chandrasekaran S, Veronica J, Sundar S, Maurya R. Alcoholic Fractions F5 and F6 from *Withaniasomnifera* Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis. *Front Med (Lausanne).* 12; 4:55, 2017. PMID: 28553635
- 116.** Tiwary P, Singh SK, Kushwaha AK, Rowton E, Sacks D, Singh OP, Sundar S, Lawyer P. Establishing, Expanding, and Certifying a Closed Colony of *Phlebotomus argentipes* (Diptera: Psychodidae) for Xenodiagnostic Studies at the Kala Azar Medical Research Center, Muzaffarpur, Bihar, India. *J Med Entomol.* 54(5):1129-1139, 2017. PMID: 28525618
- 117.** Chowdhury SR, Kumar A, Godinho JLP, De Macedo Silva ST, Zuma AA, Saha S, Kumari N, Rodrigues JCF, Sundar S, Dujardin JC, Roy S, De Souza W, Mukhopadhyay S, Majumder HK. Voacamine alters *Leishmania* ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB. *Biochem Pharmacol.* 138:19-30, 2017. PMID: 28483460
- 118.** Lahiry S, Khanra S, Kumar R, Chakraborty A, Sundar S, Sudarshan M, Manna M. Particle induced X-ray emission study of blood samples of Indian Kala-azar patients. *J Parasit Dis.* 41(1):193-198, 2017. PMID: 28316411
- 119.** Singh N, Sundar S. Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. *Exp Parasitol.* 176:30-45, 2017. PMID: 28263760
- 120.** Singh N, Sundar S. Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells. *Mol Immunol.* 85:111-119, 2017. PMID: 28222329
- 121.** Olliaro PL, Shamsuzzaman TA, Marasini B, Dhariwal AC, Be-Nazir A, Mondal D, Banjara MR, Das P, Sundar S, Rijal S, Arana B, Alvar J, Argaw D, Peeling RW, Kroeger A, Matlashewski G. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of *Leishmania* in the Indian Subcontinent. *PLoS Negl Trop Dis.* 11(1):e0005190, 2017. PMID: 28125596.

- 122.** Davis RE, Sharma S, Conceição J, Carneiro P, Novais F, Scott P, Sundar S, Bacellar O, Carvalho EM, Wilson ME. Phenotypic and functional characteristics of HLA-DR+ neutrophils in Brazilians with cutaneous leishmaniasis. *J Leukoc Biol.* 101(3):739-749, 2016 PMID 28076241
- 123.** Pandey RK, Mehrotra S, Sharma S, Gudde RS, Sundar S, Shaha C. Leishmania donovani-Induced Increase in Macrophage Bcl-2 Favors Parasite Survival. *Front Immunol.* 7:456, 2016. PMID: 27826299
- 124.** Sharma S, Davis RE, Srivastva S, Nylén S, Sundar S, Wilson ME. A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis. *J Infect Dis.* 214(10):1531-1538, 2016. PMID: 27601622
- 125.** Chauhan IS, Shukla R, Krishna S, Sekhri S, Kaushik U, Baby S, Pal C, Siddiqi MI, Sundar S, Singh N. Recombinant Leishmania Rab6 (rLdRab6) is recognized by sera from visceral leishmaniasis patients. *Exp Parasitol.* 170:135-147, 2016 .PMID: 27666959
- 126.** Pandey RK, Verma P, Sharma D, Bhatt TK, Sundar S, Prajapati VK. High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. *Biomed Pharmacother.* 141-152, 2016. PMID: 27470561
- 127.** Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. *Lancet Infect Dis.* 16(12):e304-e309, 2016. PMID: 27692643
- 128.** Ravinetto R, Becker SL, Sacko M, El-Safi S, Mahendradhata Y, Lutumba P, Rijal S, Lim K, Sundar S, N'Goran EK, Verdonck K, Utzinger J, Chappuis F, Boelaert M. Governance and Standards in International Clinical Research: The Role of Transnational Consortia. *Am J Bioeth.* 16(10):59-61, 2016. PMID: 27653405
- 129.** Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. *Ther Adv Infect Dis.* 3(3-4):98-109, 2016. PMID: 27536354
- 130.** Abeijon C, Singh OP, Chakravarty J, Sundar S, Campos-Neto A. Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. *Am J Trop Med Hyg.* pii: 16-0291, 2016. PMID: 27481058
- 131.** Chakravarty J, Kansal S, Tiwary N, Sundar S. Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. *Indian J Community Med.* 41(3):241-4, 2016. PMID: 27385880
- 132.** Singh N, Kumar R, Engwerda C, Sacks D, Nylén S, Sundar S. Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN- γ production by spleen cells from human visceral leishmaniasis patients. *Cytokine.* 85:184-90, 2016. PMID: 27372917

- 133.** Pandey RK, Kumbhar BV, Sundar S, Kunwar A, Prajapati VK. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaboroleanalogs as potential inhibitor against *Leishmania donovani* trypanothione reductase. *J Recept Signal Transduct Res.* 1-11, 2016. PMID: 27147242
- 134.** Joshi S, Yadav NK, Rawat K, Tripathi CD, Jaiswal AK, Khare P, Tandon R, Baharia RK, Das S, Gupta R, Kushawaha PK, Sundar S, Sahasrabudhe AA, Dube A. Comparative Analysis of Cellular Immune Responses in Treated *Leishmania* Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of *Leishmania donovani*. *Front Microbiol.* 7:312, 2016. PMID: 27047452
- 135.** Imamura H, Downing T, Van den Broeck F, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaerschot M, Berg M, De Muylder G, Dumetz F, Cuypers B, Maes I, Domagalska M, Decuypere S, Rai K, Uranw S, Bhattarai NR, Khanal B, Prajapati VK, Sharma S, Stark O, Schönián G, De Koning HP, Settimo L, Vanhollebeke B, Roy S, Ostyn B, Boelaert M, Maes L, Berriman M, Dujardin JC, Cotton JA. Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. *Elife.* 5. pii: e12613, 2016. PMID: 27003289
- 136.** Chakravarty J, Chourasia A, Thakur M, Singh AK, Sundar S, Agrawal NR. Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. *Indian J Med Res.* 143(1):79-86, 2016. PMID: 26997018
- 137.** Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. *Infect Dis Poverty.* 5(1):19, 2016. PMID: 26951132
- 138.** Pandey RK, Sundar S, Prajapati VK. Differential Expression of miRNA Regulates T Cell Differentiation and Plasticity During Visceral Leishmaniasis Infection. *Front Microbiol.* 7:206, 2016. PMID: 26941729
- 139.** Khare P, Jaiswal AK, Tripathi CD, Sundar S, Dube A. Immunoprotective responses of Th1 stimulatory protein- S-Adenosyl-L-Homocysteine Hydrolase against Experimental visceral Leishmaniasis. *Clin Exp Immunol.* 185(2):165-79, 2016. PMID: 26898994
- 140.** Chakravarty J, Sharma S, Johri A, Chourasia A, Sundar S. Clinical Abacavir Hypersensitivity Reaction among Children in India. *Indian J Pediatr.* 83(8):855-8, 2016
.PMID: 26887762
- 141.** Faleiro RJ, Kumar R, Bunn PT, Singh N, Chauhan SB, Sheel M, Amante FH, Montes de Oca M, Edwards CL, Ng SS, Best SE, Haque A, Beattie L, Hafner LM, Sacks D, Nylen S, Sundar S, Engwerda CR. Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. *PLoS Negl Trop Dis.* 10(2):e0004415, 2016.

PMID: 26872334

- 142.** Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR. : Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. *PLoS Pathog.* 12(2):e1005460, 2016. PMID: 26872135
- 143.** Cameron MM, Acosta-Serrano A, Bern C, Boelaert M, den Boer M, Burza S, Chapman LA, Chaskopoulou A, Coleman M, Courtenay O, Croft S, Das P, Dilger E, Foster G, Garlapati R, Haines L, Harris A, Hemingway J, Hollingsworth TD, Jervis S, Medley G, Miles M, Paine M, Picado A, Poché R, Ready P, Rogers M, Rowland M, Sundar S, de Vlas SJ, Weetman D. Understanding the transmission dynamics of *Leishmania donovani* to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. *Parasit Vectors.* 9(1):25, 2016. PMID: 26812963
- 144.** Sudarshan M, Singh T, Singh B, Chakravarty J, Sundar S. Suppression of host PTEN gene expression for *Leishmania donovani* survival in Indian visceral leishmaniasis. *Microbes Infect.* 18(5):369-72, 2016. PMID: 26774334
- 145.** Sundar S. Visceral leishmaniasis. *Trop Parasitol.* 5(2):83-5, 2015. PMID: 26629448
- 146.** Singh OP, Sundar S. Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. *J Parasitol Res.* 239469, 2015. PMID: 26843964
- 147.** Chakravarty J, Sundar S, Chourasia A, Singh PN, Kurle S, Tripathy SP, Chaturbhuj DN, Rai M, Agarwal AK, Mishra RN, Paranjape RS. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infect Dis.* 15:517, 2015. PMID: 26572102
- 148.** Chandrasekaran S, Veronica J, Gundampati RK, Sundar S, Maurya R. Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of *L. donovani*. *J Enzyme Inhib Med Chem.* 31(6):1029-37, 2015. PMID: 26406482
- 149.** Sudarshan M, Singh T, Chakravarty J, Sundar S. A Correlative Study of Splenic Parasite Score and Peripheral Blood Parasite Load Estimation by Quantitative PCR in Visceral Leishmaniasis. *J Clin Microbiol.* 53(12):3905-7, 2015. PMID: 26400788
- 150.** Kumar Pandey R, Sharma D, Kumar Bhatt T, Sundar S, Kumar Prajapati V. Developing Imidazole analogues as potential inhibitor for *Leishmania donovani* Trypanothione reductase: Virtual Screening, Molecular Docking, Dynamics and ADMET approach. *J Biomol Struct Dyn.* 33(12):2541-53, 2015. PMID: 26305585
- 151.** Das S, Shah P, Tandon R, Yadav NK, Sahasrabudhe AA, Sundar S, Siddiqi MI, Dube A. Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of *Leishmania donovani*. *PLoS Negl Trop Dis.*

9(8):e0003992, 2015.PMID: 26295340

- 152.** Mukherjee B, Paul J, Mukherjee S, Mukhopadhyay R, Das S, Naskar K, Sundar S, Dujardin JC, Saha B, Roy S. Antimony-Resistant *Leishmania donovani* Exploits miR-466i To Deactivate Host MyD88 for Regulating IL-10/IL-12 Levels during Early Hours of Infection. *J Immunol.* 195(6):2731-42, 2015.PMID: 26283478
- 153.** Zahraei-Ramazani A, Kumar D, Mirhendi H, Sundar S, Mishra R, Moin-Vaziri V, Soleimani H, Shirzadi MR, Jafari R, Hanafi-Bojd AA, Shahraky SH, Yaghoobi-Ershadi MR. Morphological and Genotypic Variations among the Species of the Subgenus *Adlerius* (Diptera: Psychodidae, Phlebotomus) in Iran. *J Arthropod Borne Dis.* 9(1):84-97, 2015.PMID: 26114146
- 154.** Prakash J, Gupta T, Prakash S, Rathore SS, Usha, Sunder S. Acute kidney injury in patients with human immunodeficiency virus infection. *Indian J Nephrol.* 25(2):86-90, 2015.PMID: 25838645
- 155.** Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Dube A. Correction: Recombinant NAD-dependent SIR-2 Protein of *Leishmania donovani*: Immunobiochemical Characterization as a Potential Vaccine against Visceral Leishmaniasis. *PLoS Negl Trop Dis.* 9(4):e0003742, 2015. PMID: 25901962
- 156.** Picado A, Ostyn B, Rijal S, Sundar S, Singh SP, Chappuis F, Das ML, Khanal B, Gidwani K, Hasker E, Dujardin JC, Vanlerberghe V, Menten J, Coosemans M, Boelaert M. Long-lasting insecticidal nets to prevent visceral leishmaniasis in the Indian subcontinent; methodological lessons learned from a cluster randomised controlled trial. *PLoS Negl Trop Dis.* 9(4):e0003597, 2015. PMID: 25856238
- 157.** Kumar A, Samant M, Misra P, Khare P, Sundar S, Dube A. Immunostimulatory potential and proteome profiling of *Leishmania donovani* soluble exogenous antigens. *Parasite Immunol.* 37(7):368-75, 2015.PMID: 25824598
- 158.** Dayakar A, Chandrasekaran S, Veronica J, Sundar S, Maurya R. In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in *Leishmania donovani* infection. *Exp Parasitol.* 153:45-54, 2015. PMID: 25747203
- 159.** Abass E, Kang C, Martinkovic F, Semião-Santos SJ, Sundar S, Walden P, Piarroux R, El Harith A, Lohoff M, Steinhoff U. Heterogeneity of *Leishmania donovani* Parasites Complicates Diagnosis of Visceral Leishmaniasis: Comparison of Different Serological Tests in Three Endemic Regions. *PLoS One.* 10(3):e0116408, 2015. PMID: 25734336
- 160.** Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in bihar, India: a retrospective cohort study. *PLoS Negl Trop Dis.* 9(3):e0003518. 2015. PMID: 25730310

- 161.** Sundar S, Singh A, Chakravarty J, Rai M. Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis. *ScientificWorldJournal*. 414378, 2015.PMID: 25685839
- 162.** Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Proteomic analyses of membrane enriched proteins of *Leishmania donovani* Indian clinical isolate by mass spectrometry. *Parasitol Int*. 64(4):36-42, 2015.PMID: 25597695
- 163.** Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis.*Expert Opin Investig Drugs*. 24(1):43-59, 2015 PMID: 25409760
- 164.** Sundar S, Singh A, Rai M, Chakravarty J. Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study. *Am J Trop Med Hyg*. 92(3):513-7, 2015. PMID: 25510715
- 165.** Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. *Expert Opin Pharmacother*. 1-16, 2014. PMID: 25346016
- 166.** Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.*Parasit Vectors*. 7(1):596, 2014. PMID: 25515494
- 167.** Sudarshan M, Singh T, Singh AK, Chourasia A, Singh B, Wilson ME, Chakravarty J, Sundar S. Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India.*PLoS Negl Trop Dis*. 8(12):e3366. , 2014. PMID: 25503103
- 168.** Jaiswal AK, Khare P, Joshi S, Rawat K, Yadav N, Sundar S, Dube A. Immunological consequences of stress-related proteins - cytosolic trypanothione peroxidase and chaperonin TCP20 - identified in splenic amastigotes of *Leishmania donovani* as Th1 stimulatory, in experimental visceral leishmaniasis. *Parasitology*. 142(5):728-44, 2014. PMID: 25498563
- 169.** Chakravarty J, Tiwary NK, Prasad SR, Shukla S, Tiwari A, Mishra RN, Sundar S. Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: A prospective study. *Indian J Med Res*. 140(4):491-500, 2014. PMID: 25488442
- 170.** Kumar D, Tiwary P, Chakravarty J, Sundar S. Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population.*ScientificWorldJournal*. 2014; 2014:852104. PMID: 25405235
- 171.** Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, Gripenberg MA, Bowes DE, Thunissen C, Singh OP, Kumar R, Ahmed O, Eisa O, Saad A, Silva Pereira S, Boelaert M, Mertens P, Miles MA. IgG1 as a Potential Biomarker of Post-chemotherapeutic Relapse in Visceral Leishmaniasis, and Adaptation to a Rapid Diagnostic Test.*PLoS Negl Trop Dis*. 8(10):e3273, 2014. PMID: 25340782

- 172.** Singh S, Sarma S, Katiyar SP, Das M, Bhardwaj R, Sundar D, Dubey VK. Probing molecular mechanism of hypericin induced parasitic death: An insight into role of spermidine beyond redox metabolism of *Leishmania*. *Antimicrob Agents Chemother.* 59(1):15-24, 2014. PMID: 25313212
- 173.** Bag AK, Saha S, Sundar S, Saha B, Chakrabarti A, Mandal C. Comparative proteomics and glycoproteomics of plasma proteins in Indian visceral leishmaniasis. *Proteome Sci.* 12(1):48, 2014. PMID: 25276097
- 174.** Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, Rai M, Sacks D, Sundar S, Nylén S. *Leishmania* specific CD4 T cells release IFN γ that limits parasite replication in patients with visceral leishmaniasis. *PLoS Negl Trop Dis.* 8(10):e3198, 2014 Oct. PMID: 25275531
- 175.** Jaiswal AK, Khare P, Joshi S, Kushawaha PK, Sundar S, Dube A. Th1 stimulatory proteins of *Leishmania donovani*: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. *PLoS One.* 9(9):e108556, 2014. PMID: 25268700
- 176.** Kumar R, Singh OP, Gautam S, Nylén S, Sundar S. Enhanced expression of Toll Like Receptors (TLRs) 2 & 4, but not 9, in spleen tissue from visceral leishmaniasis patients. *Parasite Immunol.* 36(12):721-5, 2014. PMID: 25244363
- 177.** Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. *PLoS Negl Trop Dis.* 2014 Sep 18;8(9):e3169. PMID: 25233346
- 178.** Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Roy S. Imipramine exploits histone deacetylase 11 To Increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant *Leishmania donovani* and clears organ parasites in experimental infection. *J Immunol.* 193(8):4083-94, 2014. PMID: 25217162
- 179.** Mudavath SL, Talat M, Rai M, Srivastava ON, Sundar S. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. *Drug Des Devel Ther.* 8:1235-47, 2014. PMID: 25214767
- 180.** Malaviya P, Picado A, Hasker E, Ostyn B, Kansal S, Singh RP, Shankar R, Boelaert M, Sundar S. Health & Demographic Surveillance System Profile: The Muzaffarpur-TMRC Health and Demographic Surveillance System. *Int J Epidemiol.* 43(5):1450-7, 2014. PMID: 25186307
- 181.** Malaviya P, Hasker E, Picado A, Mishra M, Van Geertruyden JP, Das ML, Boelaert M, Sundar S. Exposure to *Phlebotomus argentipes* (Diptera, Phlebotomidae,

- Phlebotominae) sand flies in rural areas of Bihar, India: the role of housing conditions. *PLoS One*. 9(9):e106771, 2014. PMID: 25184542
- 182.** Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. *Front Immunol*. 5:296, 2014. PMID: 25183962
- 183.** Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. *Lancet Glob Health*. 2(1):e51-7, 2014. PMID: 25104636
- 184.** Guha R, Das S, Ghosh J, Sundar S, Dujardin JC, Roy S. Antimony resistant *Leishmania donovani* but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF- β in early immune response. *PLoS Negl Trop Dis*. 8(7):e2995, 2014. PMID: 25032977
- 185.** Sudarshan M, Sundar S. Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. *Diagn Microbiol Infect Dis*. 80(1):40-2, 2014. PMID: 25023070
- 186.** Meena LP, Pandey SK, Rai M, Bharti A, Chakravarty J, Sundar S. Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. *J Educ Health Promot*. 3:31, 2014. PMID: 25013824
- 187.** Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. *PLoS One*. 9(6):e100220, 2014. PMID: 24941345
- 188.** Baharia RK, Tandon R, Sahasrabudhe AA, Sundar S, Dube A. Nucleosomal histone proteins of *L. donovani*: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against *Leishmania* challenge in hamsters. *PLoS One*. 9(6):e97911, 2014. PMID: 24926878
- 189.** Sundar S, Singh A, Singh OP. Strategies to overcome antileishmanial drugs unresponsiveness. *J Trop Med*. 646932, 2014. PMID: 24876851
- 190.** Stauch A, Duerr HP, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Eichner M. Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. *PLoS Negl Trop Dis*. 8(4):e2810. PMID: 24762676
- 191.** Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S, Dube A. Characterization of the proliferating cell nuclear antigen of *Leishmania donovani* clinical isolates and its association with antimony resistance. *Antimicrob Agents Chemother*. 58(6):2997-3007, 2014. PMID: 24614385

- 192.** Sundar S, Singh B. Identifying vaccine targets for anti-leishmanial vaccine development. *Expert Rev Vaccines*. 13(4):489-505, 2014. PMID: 24606556
- 193.** Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON, Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. *Adv Exp Med Biol*. 808:77-91, 2014. PMID: 24595612
- 194.** Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP, Kumar R, Ahmed O, Boelaert M, Miles MA. Significantly Lower Anti-Leishmania IgG Responses in Sudanese versus Indian Visceral Leishmaniasis. *PLoS Negl Trop Dis*. 8(2):e2675. PMID: 24587456
- 195.** Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S. Asymptomatic leishmania infection: A new challenge for leishmania control. *Clin Infect Dis*. 58(10):1424-9, 2014. PMID: 24585564
- 196.** Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: Challenges and promises. *Immunobiology*. 219(4):323-8, 2014. PMID: 24571797
- 197.** Bhandari V, Sundar S, Dujardin JC, Salotra P. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in *Leishmania donovani*. *Antimicrob Agents Chemother*. 58(5):2580-5, 2014. PMID: 24550335
- 198.** Sundar S, Singh A, Tiwari A, Shukla S, Chakravarty J, M. Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. SRN Parasitol. 5I48010, 2014. PMID: 27398387
- 199.** Picado A, Ostyn B, Singh SP, Uranw S, Hasker E, Rijal S, Sundar S, Boelaert M, Chappuis F. Risk Factors for Visceral Leishmaniasis and Asymptomatic *Leishmania donovani* Infection in India and Nepal. *PLoS One*. 9(1):e87641, 2014. PMID: 24498159
- 200.** Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabudde AA, Mitra K, Sundar S, Siddiqi MI, Dube A. Characterization of Glycolytic Enzymes - rAldolase and rEnolase of *Leishmania donovani*, Identified as Th1 Stimulatory Proteins, for Their Immunogenicity and Immunoprophylactic Efficacies against Experimental Visceral Leishmaniasis. *PLoS One*. 9(1):e86073, 2014. PMID: 24475071.
- 201.** Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, Kansal S, Singh RP, Singh OP, Chourasia A, Kumar Singh A, Shankar R, Wilson ME, Khanal B, Rijal S, Boelaert M, Sundar S. Strong Association between Serological Status and Probability of Progression to Clinical Visceral Leishmaniasis in Prospective Cohort Studies in India and Nepal. *PLoS Negl Trop Dis*. 8(1):e2657, 2014. PMID: 24466361

- 202.** Goel R, Rai M, Chakravarty J, Meena LP, Tiwary NK, Sundar S, Bharti A. Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study. *J Assoc Physicians India.* 61(4):239-43, 2013. PMID: 24482962
- 203.** Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A. Efficacy of *Leishmania donovani* trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. *Parasitol Res.* 113(3):851-62, 2013. PMID: 24370734
- 204.** Das S, Shah P, Baharia RK, Tandon R, Khare P, Sundar S, Sahasrabudde AA, Siddiqi MI, Dube A. Over-Expression of 60s Ribosomal L23a Is Associated with Cellular Proliferation in SAG Resistant Clinical Isolates of *Leishmania donovani*. *PLoS Negl Trop Dis.* 7(12):e2527, 2013 . PMID: 24340105
- 205.** Van den Bogaart E, Schoone GJ, England P, Faber D, Orrling KM, Dujardin JC, Sundar S, Schallig HD, Adams ER. Simple colorimetric trypanothione reductase-based assay for high-throughput drug screening against *Leishmania* intracellular amastigotes. *Antimicrob Agents Chemother.* 58(1):527-35, 2013. PMID: 24189262.
- 206.** Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Mass spectrometry based proteomic analysis of *Leishmania donovani* soluble proteins in Indian clinical isolate. *Pathog Dis.* 70(1):84-7, 2013. PMID: 24115687
- 207.** Rai S, Bhaskar, Goel SK, Nath Dwivedi U, Sundar S, Goyal N. Role of Efflux Pumps and Intracellular Thiols in Natural Antimony Resistant Isolates of *Leishmania donovani*. *PLoS One.* 8(9):e74862, 2013. PMID: 24069359
- 208.** Kumar D, Khanal B, Tiwary P, Mudavath SL, Tiwary NK, Singh R, Koirala K, Boelaert M, Rijal S, Sundar S. Comparative evaluation of blood and serum samples in rapid immunochromatographic tests for visceral leishmaniasis. *J Clin Microbiol.* 51(12):3955-9, 2013. PMID: 24048530.
- 209.** Prajapati VK, Sharma S, Rai M, Ostry B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S. In vitro susceptibility of *Leishmania donovani* to miltefosine in Indian visceral leishmaniasis. *Am J Trop Med Hyg.* 89(4):750-4, 2013. PMID: 23980130.
- 210.** Hazra S, Ghosh S, Das Sarma M, Sharma S, Das M, Saudagar P, Prajapati VK, Dubey VK, Sundar S, Hazra B. Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of *Leishmania donovani*. *Exp Parasitol.* 135(2):407-13, 2013. PMID: 23973194
- 211.** Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, Sundar S, Nylén S. CD8 T Cell Exhaustion in Human Visceral Leishmaniasis. *J Infect Dis.* 209(2):290-9. 2013 PMID: 23922369

- 212.** Das M, Saudagar P, Sundar S, Dubey VK. Miltefosine unresponsive *Leishmania donovani* has better ability of resist reactive oxygen species. *FEBS J.* 280(19):4807-15, 2013. PMID: 23890327
- 213.** Naznin E, Kroeger A, Siddiqui NA, Sundar S, Malaviya P, Mondal D, Huda MM, Das P, Karki P, Banjara MR, Dreesch N, Gedik G. Human resource assessment for scaling up VL active case detection in Bangladesh, India and Nepal. *Trop Med Int Health.* 18(6):734-42, 2013. PMID: 23651494
- 214.** Tiwary P, Kumar D, Mishra M, Singh RP, Rai M, Sundar S. Seasonal Variation in the Prevalence of Sand Flies Infected with *Leishmania donovani*. *PLoS One.* 8(4):e61370, 2013. PMID: 23585896
- 215.** Guha R, Das S, Ghosh J, Naskar K, Mandala A, Sundar S, Dujardin JC, Roy S. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of *Leishmania (Leishmania) donovani*. *Vaccine.* 31(15):1905-15, 2013. PMID: 23499564
- 216.** Ostyn B, Malaviya P, Hasker E, Uranw S, Singh RP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project. *Trop Med Int Health.* 18(6):725-33, 2013. PMID: 23464638
- 217.** Srivastava P, Gidwani K, Picado A, Van der Auwera G, Tiwary P, Ostyn B, Dujardin JC, Boelaert M, Sundar S. Molecular and serological markers of *Leishmania donovani* infection in healthy individuals from endemic areas of Bihar, India. *Trop Med Int Health.* 18(5):548-54, 2013. PMID: 23464581
- 218.** Hasker E, Kansal S, Malaviya P, Gidwani K, Picado A, Singh RP, Chourasia A, Singh AK, Shankar R, Menten J, Wilson ME, Boelaert M, Sundar S. Latent infection with *Leishmania donovani* in highly endemic villages in Bihar, India. *PLoS Negl Trop* 7(2):e2053 , 2013. PMID: 23459501
- 219.** Singh N, Chikara S, Sundar S. SOLiD™ sequencing of genomes of clinical isolates of *Leishmania donovani* from India confirm leptomonas co-infection and raise some key questions. *PLoS One.* 8(2):e55738, 2013. PMID: 23418454
- 220.** Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in *Leishmania donovani* promastigotes by withanolides. *Parasitol Int.* 62(3):253-61, 2013. PMID: 23416156
- 221.** Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, Allam US, Chakravorty D, Sundar S, Dujardin JC, Roy S. Antimony-resistant but not antimony-sensitive *Leishmania donovani* up-regulates host IL-10 to overexpress multidrug-resistant protein 1. *Proc Natl Acad Sci U S A.* 110(7):E575-82, 2013. PMID: 23341611

- 222.** LeishGEN Consortium; Wellcome Trust Case Control Consortium 2, Fakiola M, Strange A, Cordell HJ, Miller EN, Pirinen M, Su Z, Mishra A, Mehrotra S, Monteiro GR, Band G, Bellenguez C, Dronov S, Edkins S, Freeman C, Giannoulidou E, Gray E, Hunt SE, Lacerda HG, Langford C, Pearson R, Pontes NN, Rai M, Singh SP, Smith L, Sousa O, Vukcevic D, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Wilson ME, Deloukas P, Peltonen L, Christiansen F, Witt C, Jeronimo SM, Sundar S, Spencer CC, Blackwell JM, Donnelly P. Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. *Nat Genet.* 45(2):208-13, 2013. PMID: 23291585
- 223.** Malaviya P, Ravinetto R, Sundar S. Ethical research is grounded in quality data: a clinical data management workshop in Varanasi. *Indian J Med Ethics.* 10(2):132, 2013. PMID: 23697499
- 224.** Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. *Vaccine.* 31 Suppl 2:B244-9, 2013. PMID: 23598489
- 225.** Sundar S, Singh A. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis? *Expert Rev Anti Infect Ther.* 11(2):117-9, 2013. PMID: 23409817
- 226.** Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. *Expert Opin Pharmacother.* 14(1):53-63, 2013. PMID: 23256501
- 227.** Malaviya P, Hasker E, Singh RP, Van Geertruyden JP, Boelaert M, Sundar S. Village health workers in Bihar, India: an untapped resource in the struggle against kala-azar. *Trop Med Int Health.* 18(2):188-93, 2013. PMID: 23279554
- 228.** Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of *Leishmania donovani*. *Parasitol Res.* 112(2):825-8, 2013. PMID: 23239091
- 229.** Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. *Trop Med Int Health.* 18(1):96-100, 2013. PMID: 23136856
- 230.** Kumar P, Kumar R, Pandey H, Sundar S, Pai K. Studies on the arginase, 5'-nucleotidase and lysozyme activity by monocytes from visceral leishmaniasis patients. *J Parasit Dis.* 36(1):19-25, 2012. PMID: 23542635
- 231.** Singh OP, Sundar S. Analysis of Total Urine Proteins: Towards A Non-Invasive Approach for Diagnosis of Visceral Leishmaniasis. *J Mol Biomark Diagn.* 3(131), 2012. PMID: 23503981

- 232.** Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Das AK, Roy S. Imipramine is an orally active drug against both antimony sensitive and resistant *Leishmania donovani* clinical isolates in experimental infection. *PLoS Negl Trop Dis.* 6(12):e1987, 2012. PMID: 23301108
- 233.** Picado A, Rijal S, Sundar S, Boelaert M. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable. *Expert Rev Anti Infect Ther.* 10(8):839-41, 2012. PMID: 23030320
- 234.** Sundar S, Chakravarty J. Recent advances in the diagnosis and treatment of kala-azar. *Natl Med J India.* 25(2):85-9, 2012. PMID: 22686715
- 235.** Sundar S, Prajapati VK. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. *Curr Med Chem.* 19(19):3196-202, 2012. PMID: 22612703
- 236.** Singh B, Sundar S. Leishmaniasis: Vaccine candidates and perspectives. *Vaccine.* 30(26):3834-42, 2012. PMID: 22475861
- 237.** Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M. Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant *L. donovani* in Bihar, India. *PLoS Negl Trop Dis.* 6(12):e1973, 2012. PMID: 23285309
- 238.** Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M. Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India. *Trop Med Int Health.* 2012 Dec 28. PMID: 23279744
- 239.** Tiwary P, Kumar D, Rai M, Sundar S. PCR-RFLP based method for molecular differentiation of sand fly species *Phlebotomus argentipes*, *Phlebotomus papatasi*, and *Sergentomyia babu* found in India. *J Med Entomol.* 2012; 49:1515-8. PMID: 23270185
- 240.** Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. *PLoS Negl Trop Dis.* 6(10):e1874, 2012. PMID: 23150744.
- 241.** Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, Dube A. *Leishmania donovani* Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis. *PLoS One.* 7(9):e45766, 2012. PMID: 23049855
- 242.** A, Chandrasekaran S, Prajapati VK, Veronica J, Sundar S, Maurya R. A rapid method to assess the stage differentiation in *Leishmania donovani* by flow cytometry. *Exp Parasitol.* 132(4):495-500, 2012. PMID: 23022521
- 243.** Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S. Visceral leishmaniasis in rural Bihar, India. *Emerg Infect Dis.* 18(10):1662-4, 2012. PMID: 23017164

- 244.** Pulimood SA, Rupali P, Ajjampur SS, Thomas M, Mehrotra S, Sundar S. Atypical mucocutaneous involvement with *Leishmania donovani*. *Natl Med J India*. 25(3):148-50, 2012. PMID: 22963292
- 245.** Cunningham J, Hasker E, Das P, El Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M; for the WHO/TDR Visceral Leishmaniasis Laboratory Network. A Global Comparative Evaluation of Commercial Immunochromatographic Rapid Diagnostic Tests for Visceral Leishmaniasis. *Clin Infect Dis*. 55(10):1312-9, 2012. PMID: 22942208
- 246.** Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S. In vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis--Status of Newly Introduced Drugs. *Am J Trop Med Hyg*. 87(4):655-7, 2012.. PMID: 22927497
- 247.** Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. *Trop Med Int Health*. 17(11):1345-8, 2012. PMID: 22882665
- 248.** Vaish M, Sharma S, Chakravarty J, Sundar S. Evaluation of rKE16 antigen based two novel rapid diagnostic tests for diagnosis of Visceral Leishmaniasis in India. *J Clin Microbiol*. 50(9):3091-2, 2012. PMID: 22760038
- 249.** Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, Roy S, Ostyn B, Maes L, Khanal B, Boelaert M, Schönian G, Berriman M, Chappuis F, Dujardin JC, Sundar S, Rijal S. Genetic markers for SSG-resistance in *Leishmania donovani* and SSG-treatment failure in visceral leishmaniasis patients of the Indian subcontinent. *J Infect Dis*. 206(5):752-5, 2012. PMID: 22753945
- 250.** Hendrickx S, Inocêncio da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L. Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of *L. donovani*: Outcome Dependent on In Vitro Selection Protocol. *PLoS Negl Trop Dis*. 6(5):e1664, 2012. PMID: 22666513
- 251.** Olliaro P, Vaillant MT, Sundar S, Balasegaram M. More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. *PLoS Negl Trop Dis*. 6(5):e1545, 2012. PMID: 22666508
- 252.** Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P. Drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. *PLoS Negl Trop Dis*. 6(5):e1657, 2012 . PMID: 22629478

- 253.** Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis after a Decade of use in India. *Clin Infect Dis.* 55(4):543-50, 2012. PMID: 22573856
- 254.** Mehrotra S, Fakiola M, Mishra A, Sudharshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India. *Infect Genet Evol.* 12(6):1195-201, 2012. PMID: 22561395
- 255.** Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of *Leishmania donovani* Protein Disulfide Isomerase as a Potential Immunogenic Protein/Vaccine Candidate against Visceral Leishmaniasis. *PLoS One.* 7(4):e35670, 2012. PMID: 22539989
- 256.** Singh OP, Gidwani K, Kumar R, Jones SL, Boelaert M, Sacks D, Sundar S. A reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. *Clin Vaccine Immunol.* 19(6):961-6, 2012. PMID: 22539471
- 257.** Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant *Leishmania donovani* p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. *Int J Parasitol.* 42(5):429-35, 2012. PMID: 22502587
- 258.** Kumar S, Kumar D, Chakravarty J, Rai M, Sundar S. Identification and Characterization of a Novel *Leishmania donovani* Antigen for Serodiagnosis of Visceral Leishmaniasis. *Am J Trop Med Hyg.* 86(4):601-5, 2012. PMID: 22492143
- 259.** Vaish M, Singh OP, Chakravarty J, Sundar S. rK39 Antigen for the Diagnosis of Visceral Leishmaniasis by Using Human Saliva. *Am J Trop Med Hyg.* 86(4):598-600, 2012. PMID: 22492142
- 260.** Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B. Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7-dibromocryptolepine against *Leishmania donovani* promastigotes. *Parasitol Res.* 111(1):195-203. PMID: 22297912
- 261.** Kumari S, Misra P, Tandon R, Samant M, Sundar S, Dube A. *Leishmania donovani*: Immunostimulatory Cellular Responses of Membrane and Soluble Protein Fractions of Splenic Amastigotes in Cured Patient and Hamsters. *PLoS One.* 7(1):e30746, 2012. PMID: 22292030
- 262.** Tiwary P, Kumar D, Singh RP, Rai M, Sundar S. Prevalence of Sand Flies and *Leishmania donovani* Infection in a Natural Population of Female *Phlebotomus argentipes* in Bihar State, India. *Vector Borne Zoonotic Dis.* 12(6):467-72, 2012. PMID: 22217179

- 263.** Prajapati VK, Awasthi K, Yadav TP, Rai M, Srivastava ON, Sundar S. An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes Is an Effective Treatment for Experimental Visceral Leishmaniasis. *J Infect Dis.* 205(2):333-6, 2012. PMID: 22158723
- 264.** Picado A, Singh SP, Vanlerberghe V, Uranw S, Ostyn B, Kaur H, Das ML, Sundar S, Rijal S, Tungu P, Boelaert M, Rowland M. Residual activity and integrity of PermaNet(®) 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. *Trans R Soc Trop Med Hyg.* 106(3):150-9, 2012. PMID: 22137191
- 265.** Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, Decuypere S, de Doncker S, Maes I, Rijal S, Sundar S, Dujardin JC, Berriman M, Schönian G. Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the *Leishmania donovani* species complex. *Infect Genet Evol.* 12(1):149-59, 2012. PMID: 22119748
- 266.** Ashutosh, Garg M, Sundar S, Duncan R, Nakhasi HL, Goyal N. MAP Kinase1 of *Leishmania donovani*: Down Regulation Associates With Antimony Resistance in Field Isolates. *Antimicrob Agents Chemother.* 56(1):518-25, 2012. PMID: 22064540
- 267.** Vaish M, Bhatia A, Reed SG, Chakravarty J, Sundar S. Evaluation of rK28 antigen for serodiagnosis of visceral Leishmaniasis in India. *Clin Microbiol Infect.* 18(1):81-5, 2012. PMID: 21722262
- 268.** Mehrotra S, Fakiola M, Oommen J, Jamieson SE, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India. *BMC Med Genet.* 12(1):162, 2011. PMID: 22171941
- 269.** Samanta S, Dutta D, Ghoshal A, Mukhopadhyay S, Saha B, Sundar S, Jarmalavicius S, Forgher M, Mandal C, Walden P, Mandal C. Glycosylation of Erythrocyte Spectrin and Its Modification in Visceral Leishmaniasis. *PLoS One.* 6(12):e28169, 2011. PMID: 22164239
- 270.** Sinha PK, Jha TK, Thakur CP, Nath D, Mukherjee S, Aditya AK, Sundar S. Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India. *J Trop Med.* 645203, 2011. PMID: 22174722
- 271.** Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. *PLoS Negl Trop Dis.* 5(11):e1405, 2011. PMID: 22140589
- 272.** Kushawaha PK, Gupta R, Sundar S, Sahasrabudde AA, Dube A. Elongation Factor-2, a Th1 Stimulatory Protein of *Leishmania donovani*, Generates Strong IFN- γ and IL-12 Response in Cured *Leishmania*-Infected Patients/Hamsters and Protects Hamsters against *Leishmania* Challenge. *J Immunol.* 187(12):6417-27, 2011. PMID: 22079980

- 273.** Weirather JL, Jeronimo SM, Gautam S, Sundar S, Kang M, Kurtz MA, Haque R, Schriefer A, Talhari S, Carvalho EM, Donelson JE, Wilson ME. Serial Quantitative PCR Assay for Detection, Species Discrimination, and Quantification of *Leishmania* spp. in Human Samples. *J Clin Microbiol.* 49(11):3892-904, 2011. PMID: 22042830
- 274.** Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. *Genome Res.* 21(12):2143-56, 2011. PMID: 22038251
- 275.** Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, Rijal S, Sundar S, Boelaert M. incidence of Symptomatic and Asymptomatic *Leishmania donovani* Infections in High-Endemic Foci in India and Nepal: A Prospective Study. *PLoS Negl Trop Dis.* 5(10):e1284, 2011. PMID: 21991397
- 276.** Kumar N, Singh SP, Mondal D, Joshi A, Das P, Sundar S, Kroeger A, Hirve S, Siddiqui NA, Boelaert M. How do health care providers deal with kala-azar in the Indian subcontinent? *Indian J Med Res.* 134(3):349-55, 2011. PMID: 21985818
- 277.** Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent? *PLoS Negl Trop Dis.* 5(9):e1227, 2011. PMID: 21980542
- 278.** Kumar D, Kumar S, Chakravarty J, Sundar S. A Novel 12.6-kDa Protein of *Leishmania donovani* for the Diagnosis of Indian Visceral Leishmaniasis. *Vector Borne Zoonotic Dis.* 11(10):1359-64, 2011. PMID: 21923256
- 279.** Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, Decuypere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of antimony-resistant *Leishmania donovani* isolates: Biochemical and biophysical studies and interaction with host cells. *Int J Parasitol.* 41(13-14):1311-21, 2011. PMID: 21920365
- 280.** Srivastava P, Singh T, Sundar S. Genetic Heterogeneity in Clinical Isolates of *Leishmania donovani* from India. *J Clin Microbiol.* 49(10):3687-90, 2011. PMID: 21865422
- 281.** Gidwani K, Picado A, Rijal S, Singh SP, Roy L, Volfova V, Andersen EW, Uranw S, Ostyn B, Sudarshan M, Chakravarty J, Volf P, Sundar S, Boelaert M, Rogers ME. Serological Markers of Sand Fly Exposure to Evaluate Insecticidal Nets against Visceral Leishmaniasis in India and Nepal: A Cluster-Randomized Trial. *PLoS Negl Trop Dis.* 5(9):e1296, 2011. PMID: 21931871

- 282.** Gautam S, Kumar R, Maurya R, Nylén S, Ansari N, Rai M, Sundar S, Sacks D. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. *J Infect Dis.* 204(7):1134-7, 2011. PMID: 21881130
- 283.** Ouakad M, Vanaerschot M, Rijal S, Sundar S, Speybroeck N, Kestens L, Boel L, DE Doncker S, Maes I, Decuypere S, Dujardin JC. Increased metacyclogenesis of antimony-resistant *Leishmania donovani* clinical lines. *Parasitology.* 138(11):1392-9, 2011. PMID: 21819638
- 284.** Meena LP, Rai M, Singh SK, Chakravarty J, Singh A, Goel R, Pathak A, Sundar S. Endocrine changes in male HIV patients. *J Assoc Physicians India.* 59:365-6, 371, 2011. PMID: 21751590
- 285.** Fakiola M, Miller EN, Fadl M, Mohamed HS, Jamieson SE, Francis RW, Cordell HJ, Peacock CS, Raju M, Khalil EA, Elhassan A, Musa AM, Silveira F, Shaw JJ, Sundar S, Jeronimo SM, Ibrahim ME, Blackwell JM. Genetic and Functional Evidence Implicating *DLL1* as the Gene That Influences Susceptibility to Visceral Leishmaniasis at Chromosome 6q27. *J Infect Dis.* 204(3):467-77, 2011. PMID: 21742847
- 286.** Chakravarty J, Kumar S, Kumar R, Gautam S, Rai M, Sundar S. Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 105(9):537-9, 2011. PMID: 21708392
- 287.** Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of Oral Sitamaquine Taken with or without Food and Safety and Efficacy for Treatment of Visceral Leishmaniasis: A Randomized Study in Bihar, India. *Am J Trop Med Hyg.* 84(6):892-900, 2011. PMID: 21633025
- 288.** Malaviya P, Singh RP, Singh SP, Hasker E, Ostyn B, Shankar R, Boelaert M, Sundar S. Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system. *Trop Med Int Health.* 16(9):1159-66, 2011. PMID: 21624015
- 289.** Srivastava P, Prajapati VK, Rai M, Sundar S. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. *J Clin Microbiol.* 49:3088-91, 2011. PMID: 21613432
- 290.** Mohan S, Srivastava P, Maheshwari SN, Sundar S, Prakash R. Nano-structured nickel oxide based DNA biosensor for detection of visceral leishmaniasis (Kala-azar). *Analyst.* 136:2845-51, 2011. PMID: 21611668
- 291.** Sudarshan M, Weirather JL, Wilson ME, Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. *J Antimicrob Chemother.* 66 :1751-5, 2011. PMID: 21609983
- 292.** Mehrotra S, Oommen J, Mishra A, Sudharshan M, Tiwary P, Jamieson SE, Fakiola M, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. No evidence for association between *SLC11A1* and visceral leishmaniasis in India. *BMC Med Genet.* 12 :71, 2011. PMID: 21599885

- 293.** Srivastava P, Mehrotra S, Tiwary P, Chakravarty J, Sundar S. Diagnosis of Indian visceral leishmaniasis by nucleic Acid detection using PCR. *PLoS One*. 6(4):e19304, 2011. PMID: 21559398
- 294.** Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-Gamma Release Assay (Modified QuantiFERON) as a Potential Marker of Infection for *Leishmania donovani*, a Proof of Concept Study. *PLoS Negl Trop Dis*. 5(4):e1042, 2011. PMID: 21526219
- 295.** Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Lima MA, Ritmeijer K, Costa CH, Costa DL, Rijal S, Sundar S, Balasegaram M. Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia. *Am J Trop Med Hyg*. 84(4):543-550, 2011. PMID: 21460007
- 296.** Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J. Visceral leishmaniasis: elimination with existing interventions. *Lancet Infect Dis*. 11(4):322-5, 2011. PMID: 21453873
- 297.** Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of Visceral leishmaniasis. *Vaccine*. 29(19):3531-7, 2011. PMID: 21414377
- 298.** Kumar S, Kumar D, Chakravarty J, Sundar S. Identification and characterization of a novel 37 kDa *Leishmania donovani* Antigen for Diagnosis of Indian Visceral Leishmaniasis. *Clin Vaccine Immunol*. 18(5):772-5, 2011. PMID: 21411602
- 299.** Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S. Targeted killing of *Leishmania donovani* in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. *J Antimicrob Chemother*. 66(4):874-9, 2011. PMID: 21393222
- 300.** Malaviya P, Picado A, Singh SP, Hasker E, Singh RP, Boelaert M, Sundar S. Visceral leishmaniasis in muzaffarpur district, bihar, India from 1990 to 2008. *PLoS One*. 6(3):e14751, 2011. PMID: 21394195
- 301.** Vaish M, Mehrotra S, Chakravarty J, Sundar S. Noninvasive Molecular Diagnosis of Human Visceral Leishmaniasis. *J Clin Microbiol*. 49(5):2003-5, 2011. PMID: 21389158.
- 302.** Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S, Sacks D. IL-27 and IL-21 are associated with T Cell IL-10 responses in Human Visceral Leishmaniasis. *J Immunol*. 186(7):3977-85, 2011. PMID: 21357266
- 303.** Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D, Sundar S, Das P, Gurung CK, Rijal S, Thakur CP, Varghese B, Kroeger A. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and

- bangladesh, comparing yield, feasibility and costs. *PLoS Negl Trop Dis.* 8;5:e960, 2011. PMID: 21347452
- 304.** Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. *Lancet.* 377 :477-86, 2011. PMID: 21255828
- 305.** Fakiola M, Mishra A, Rai M, Singh SP, O'Leary RA, Ball S, Francis RW, Firth MJ, Radford BT, Miller EN, Sundar S, Blackwell JM. Classification and regression tree and spatial analyses reveal geographic heterogeneity in genome wide linkage study of Indian visceral leishmaniasis. *PLoS One.* 5(12):e15807, 2010.PMID: 21209823
- 306.** Picado A, Singh SP, Rijal S, Sundar S, Ostyn B, Chappuis F, Uranw S, Gidwani K, Khanal B, Rai M, Paudel IS, Das ML, Kumar R, Srivastava P, Dujardin JC, Vanlerberghe V, Andersen EW, Davies CR, Boelaert M. Longlasting insecticidal nets for prevention of *Leishmania donovani* infection in India and Nepal: paired cluster randomised trial. *BMJ.* 341:c6760, 2010.PMID: 21190965
- 307.** Singodia D, Gupta GK, Verma A, Singh V, Shukla P, Misra P, Sundar S, Dube A, Mishra PR. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis. *J Biomed Nanotechnol.* 6(3):293-302, 2010.PMID: 21179947
- 308.** Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.. *Indian J Med Res.* 132:386-9, 2010.PMID: 20966515
- 309.** Dujardin JC, Herrera S, do Rosario V, Arevalo J, Boelaert M, Carrasco HJ, Correa-Oliveira R, Garcia L, Gotuzzo E, Gyorkos TW, Kalergis AM, Kouri G, Larraga V, Lutumba P, Macias Garcia MA, Manrique-Saide PC, Modabber F, Nieto A, Pluschke G, Robello C, Rojas de Arias A, Rumbo M, Santos Preciado JI, Sundar S, Torres J, Torrico F, Van der Stuyft P, Victoir K, Olesen OF. Research priorities for neglected infectious diseases in Latin America and the Caribbean region. *PLoS Negl Trop Dis.* 4(10):e780, 2010.PMID: 21049009
- 310.** Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, Lejon V, Chappuis F, Boelaert M, Sundar S. Note: Persistence of *Leishmania donovani* antibodies in past Visceral Leishmaniasis cases in India.*Clin. Vaccine Immunol.* 18(2):346-8, 2010. PMID: 21159922
- 311.** Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar.*Trans R Soc Trop Med Hyg.* 105(2):115-7. PMID: 21129762

- 312.** Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S. Detection of *Leptomonas* sp. parasites in clinical isolates of Kala-azar patients from India. *Infect Genet Evol.* 10 :1145–1150, 2010. PMID: 20633704
- 313.** Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. *PLoS Negl Trop Dis.* 4(9), 2010. pii: e818. PMID: 20838649
- 314.** Agarwal D, Narayan S, Chakravarty J, Sundar S. Ultrasonography for diagnosis of abdominal tuberculosis in HIV infected people. *Indian J Med Res.* 132: 77-80, 2010 . PMID: 20693594
- 315.** Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of *Leishmania donovani*. *Br J Clin Pharmacol.* 70 :609-17, 2010. PMID: 20840452
- 316.** Hirve S, Singh SP, Kumar N, Banjara MR, Das P, Sundar S, Rijal S, Joshi A, Kroeger A, Varghese B, Thakur CP, Huda MM, Mondal D. Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. *Am J Trop Med Hyg.* 83 :507-11, 2010. PMID: 20810811
- 317.** Singh DP, Goyal RK, Singh RK, Sundar S, Mohapatra TM. In search of an ideal test for diagnosis and prognosis of kala-azar. *J Health Popul Nutr.* 28(3):281-5, 2010. PMID: 20635639
- 318.** Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, Nylén S. Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen. *Parasite Immunol.* 32: 479-83, 2010. PMID: 20591118
- 319.** Hasker E., Singh SP, Malaviya P, Singh RP, Shankar R, Boelaert M, Sundar S. Management of visceral leishmaniasis in rural primary health care services in Bihar, India *Trop Med Int Health.* 15 Suppl 2:55-62, 2010. PMID: 20591081
- 320.** Mishra RN, Singh SP, Vanlerberghe V, Sundar S, Boelaert M, Lefèvre P. Lay perceptions of kala-azar, mosquitoes and bed nets in Bihar, India. *Trop Med Int Health.* 15 (Suppl):36-41, 2010. PMID: 20591080
- 321.** Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of trypanothione peroxidase in antimony unresponsive *Leishmania donovani* field isolates. *Mol Biochem Parasitol.* 173(2):162-4, 2010. PMID: 20553768
- 322.** Kaur J, Sundar S, Singh N. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of *Leishmania donovani*. *J Antimicrob Chemother.* 65(8):1742-8, 2010. PMID: 20519355

- 323.** Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of Blood agar micro-titer plates for culturing *Leishmania* parasites to titrate the parasite burden in spleen and peripheral blood of VL patients. *Clin. Microbiol.* 48(5):1932-4, 2010. PMID: 20335419
- 324.** Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. *N Engl J Med.* 362: 504-12, 2010. PMID: 20147716
- 325.** Singh SP, Hasker E, Picado A, Gidwani K, Malaviya P, Singh RP, Boelaert M, Sundar S. Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. *Trop Med Int Health.* 15 (Suppl):29-35, 2010. PMID: 20487424
- 326.** Singh SP, Picado A, Boelaert M, Gidwani K, Andersen EW, Ostyn B, Meheus F, Rai M, Chappuis F, Davies C, Sundar S. The epidemiology of *Leishmania donovani* infection in high transmission foci in India. *Trop Med Int Health.* 15 (Suppl):12-20, 2010. PMID:20487420
- 327.** Sundar S, Arora R, Singh SP, Boelaert M, Varghese B. Household-cost-of-illness of visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 15 (Suppl):50-54 , 2010. PMID: 20487419
- 328.** Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. *Am J Trop Med Hyg.* 82(5):808-13, 2010. PMID: 20439959
- 329.** Clements MF, Gidwani K, Kumar R, Hostomska J, Dinesh DS, Kumar V, Das P, Müller I, Hamilton G, Volfova V, Boelaert M, Das M, Rijal S, Picado A, Volf P, Sundar S, Davies CR, Rogers ME. Measurement of recent exposure to *Phlebotomus argentipes*, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. *Am J Trop Med Hyg.* 82(5):801-7, 2010. PMID: 20439958
- 330.** Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S. Comparative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. *J Infect Dev Ctries.* 4:114-7, 2010. PMID: 20439958
- 331.** Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR. Effect of Village-wide Use of Long-Lasting Insecticidal Nets on Visceral Leishmaniasis Vectors in India and Nepal: A Cluster Randomized Trial. *PLoS Negl Trop Dis.* 4(1): e587, 2010. PMID: 20126269
- 332.** Tuli L, Singh DK, Gulati AK, Sundar S, Mohapatra TM. A multiattribute utility evaluation of different methods for the detection of enteric protozoa causing diarrhea in AIDS patients. *BMC Microbiology.* 10:11, 2010. PMID: 20078872
- 333.** Sundar S, Chakravarty J. Antimony Toxicity. *Int. J. Environ. Res. Public Health.* 7(12):4267-77, 2010. PMID: 21318007

- 334.** Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 105(1):1-6, 2010. PMID: 21074233
- 335.** Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. *J Glob Infect Dis.* (2):159-66, 2010. PMID: 20606972
- 336.** Chakravarty J, Sundar S. Drug resistance in leishmaniasis. *J Glob Infect Dis.* 2(2):167-76, 2010. PMID: 20606973
- 337.** Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing *Leishmania* species of visceral and cutaneous forms. *Acta Trop.* 113(2):202-6, 2009. PMID: 19854144
- 338.** Picado A, Kumar V, Das M, Burniston I, Roy L, Suman R, Dinesh D, Coosemans M, Sundar S, Shreekant K, Boelaert M, Davies C, Cameron M. Effect of untreated bed nets on blood-fed *Phlebotomus argentipes* in kala-azar endemic foci in Nepal and India. *Mem Inst Oswaldo Cruz.* 104: 1183-1186, 2009. PMID: 20140382
- 339.** Singh DP, Sundar S, Mohapatra TM. The rK39 strip test is non-predictor of clinical status for kala-azar. *BMC Res Notes.* 2:187, 2009. PMID: 19772616
- 340.** Vanlerberghe V, Singh SP, Paudel IS, Ostyn B, Picado A, Sánchez A, Rijal S, Sundar S, Davies C, Boelaert M. Determinants of bednet ownership and use in visceral leishmaniasis-endemic areas of the Indian subcontinent. *Trop Med Int Health.* 15(1):60-7, 2009. PMID: 19917036
- 341.** Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment. *Clin Infect Dis.* 49:914–8, 2009. PMID: 19663597
- 342.** Sundar S, A. Singh , D. Agarwal , M. Rai , N. Agrawal , and J. Chakravarty. Safety and Efficacy of High-Dose Infusions of a Preformed Amphotericin B Fat Emulsion for Treatment of Indian Visceral Leishmaniasis. *Am. J. Trop. Med. Hyg.* 80: 700–703, 2009. PMID: 19407109
- 343.** Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14:918-25, 2009. PMID: 19563434
- 344.** Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A. Transgenic *Leishmania donovani* clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. *J Antimicrob Chemother.* 64:370-4, 2009. PMID: 19525291
- 345.** Gidwani K, Rai M, Chakravarty J, Boelaert M, Sundar S. Evaluation of leishmanin skin test in Indian visceral leishmaniasis. *Am J Trop Med Hyg.* 80:566-7, 2009. PMID: 19346376

- 346.** Sarkar A, Mandal G, Singh N, Sundar S, Chatterjee M. Flow cytometric determination of intracellular non-protein thiols in *Leishmania* promastigotes using 5-chloromethyl fluorescein diacetate. *Exp Parasitol.* 122 : 299–305, 2009. PMID: 19393240
- 347.** Boelaert M, Meheus F, Sanchez A, Singh SP, Vanlerberghe V, Picado A, Meessen B, Sundar S. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14: 639–644, 2009. PMID: 19392741
- 348.** Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A, Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME. Genetics and visceral leishmaniasis: of mice and man. *Parasite Immunol.* 31:254-66, 2009. PMID: 19388946
- 349.** Gidwani K, Kumar R, Rai M, Sundar S. Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. *Am J Trop Med Hyg.* 80: 345-6, 2009. PMID: 19270279
- 350.** Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M. Visceral Leishmaniasis Elimination Programme in India, Bangladesh, and Nepal: Reshaping the Case Finding/Case Management Strategy. *PLoS Negl Trop Dis.* 3: e355, 2009. PMID: 19159009
- 351.** Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M. Functionality of drug efflux pumps in antimonial resistant *Leishmania donovani* field isolates. *Indian J Biochem Biophysics.* 46: 86-92, 2009. PMID: 19374259
- 352.** Ghoshal A, Mukhopadhyay S, Demine R, Forger M, Jarmalavicius S, Saha B, Sundar S, Walden P, Mandal C, Mandal C. Detection and characterization of a sialoglycosylated bacterial ABC-type phosphate transporter protein from patients with visceral leishmaniasis. *Glycoconj J.* 26:675-89, 2009. PMID: 19184417
- 353.** Awanish Kumar, Vijay Raju Boggula, Shyam Sundar, Ajit Kumar Shasany and Anuradha Dube. Identification of genetic markers in Sodium Antimony Gluconate (SAG) sensitive and resistant Indian clinical isolates of *Leishmania donovani* through amplified fragment length polymorphism (AFLP). *Acta Tropica.* 110: 80–85, 2009. PMID: 19283900
- 354.** Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14 : 88–92, 2009. PMID: 19121150
- 355.** Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine. *Clin Infect Dis.* 47: 1000-1006, 2008. PMID: 18781879
- 356.** Alam MZ, Kuhls K, Schweynoch C, Sundar S, Rijal S, Shamsuzzaman AK, Raju BV, Salotra P, Dujardin JC, Schönian G. Multilocus microsatellite typing (MLMT)

- reveals genetic homogeneity of *Leishmania donovani* strains in the Indian subcontinent. *Infect Genet Evol.* 9:24-31, 2008. PMID: 18957333
- 357.** Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ. Intracellular Survival of *Leishmania* Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors. *J Infect Dis.* 198: 1292-9, 2008. PMID: 18816190
- 358.** Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S. Prophylactic Efficacy of High-Molecular-Weight Antigenic Fractions of a Recent Clinical Isolate of *Leishmania donovani* Against Visceral Leishmaniasis. *Scand J Immunol.* 68: 492-501, 2008. PMID: 18803606
- 359.** Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Induction of Th1-type cellular responses in cured/exposed *Leishmania*-infected patients and hamsters against polyproteins of soluble *Leishmania donovani* promastigotes ranging from 89.9 to 97.1 kDa. *Vaccine.* 26 :4813–4818, 2008. PMID: 18656517
- 360.** Tuli L, Gulati AK, Sundar S, Mohapatra TM. Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - An experience of a tertiary care hospital in Varanasi (India). *BMC Gastroenterol.* 8 :36, 2008. PMID: 18713475
- 361.** Chakraborty D, Basu JM, Sen P, Sundar S, Roy S. Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial. *Ann Trop Med Parasitol.* 102 :21-38, 2008. PMID: 18186975
- 362.** Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. *Trop Med Int Health.* 13: 1208–1212, 2008. PMID: 18664241
- 363.** Agarwal D, Chakravarty J, Sundar S, Gupta V, Bhatia BD. Correlation between clinical features and degree of immunosuppression in HIV infected children. *Indian Pediatr.* 45:140-3, 2008. PMID: 18310794
- 364.** Ostyn B, Vanlerberghe V, Picado A, Dinesh DS, Sundar S, Chappuis F, Rijal S, Dujardin JC, Coosemans M, Boelaert M, Davies C. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? *Trop Med Int Health.* 13 :1073-85, 2008. PMID: 18564350
- 365.** Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. *J Antimicrob Chemother.* 62: 376-80, 2008. PMID: 18453526
- 366.** Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. *Trans R Soc Trop Med Hyg.* 102, 32- 40, 2008. PMID: 17942129

- 367.** Attili SVS, Singh VP, Rai M, Varma DV, Gulati AK, Sundar S. Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Varanasi, North India. *Turk J Hematol.* 25:13-19, 2008. PMID: 27264145
- 368.** Dwivedi US, Kumar A, Das SK, Trivedi S, Kumar M, Sundar S, Singh PB. Relook TURBT in superficial bladder cancer: Its importance and its correlation with the tumor ploidy. *Urol Oncol.* 27:514-9, 2008. PMID: 18639472
- 369.** Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery & new targets for vaccine and therapeutics against visceral leishmaniasis. *Proteomics Clinical Applications.* 3: 372-386, 2008. PMID: 21136840
- 370.** Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal – the challenges for diagnosis and treatment. *Trop Med Int Health.* 13: 2–5, 2008. PMID: 18290995
- 371.** Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. *Expert Opin Investig Drugs.* 17:787-94, 2008. PMID: 18447603
- 372.** Sundar S, Olliaro P. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. *Thera Clin Risk Management.* 3: 733-40, 2007. PMID: 18472998
- 373.** Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat Rev Microbiol.* 11:873-82, 2007. PMID: 17938629
- 374.** Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. *N Engl J Med.* 356:2571-81, 2007. PMID: 17582067
- 375.** Tripathi K, Kumar R, Bharti K, Kumar P, Shrivastav R, Sundar S, Pai K. Adenosine deaminase activity in sera of patients with visceral leishmaniasis in India. *Clin Chim Acta.* 388: 135-8, 2007. PMID: 18023276
- 376.** Das ML, Singh SP, Vanlerberghe V, Rijal S, Rai M, Karki P, Sundar S, Boelaert M. Population Preference of Net Texture prior to Bed Net Trial in Kala-Azar–Endemic Areas. *Plos Neg Trop Dis.* 1: e100, 2007. PMID: 18160976
- 377.** Basu JM, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection. *Antimicrob Agents Chemother.* 52:1080-93, 2007. PMID: 18056276
- 378.** Sundar S, Singh RK, Bimal SK, Gidwani K, Mishra A, Maurya R, Singh SK, Manandhar KD, Boelaert M, Rai M. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III

- diagnostic accuracy study. *Trop Med Int Health*. 12: 284-9, 2007. PMID: 17300637
- 379.** Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate- Day Infusions. *Clin Infect Dis*. 45: 556-61, 2007. PMID: 17682988
- 380.** Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. *J Infect Dis*. 196:591-8, 2007. PMID: 17624846
- 381.** Mandal G, Wyllie S, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Increased levels of thiols protect antimony unresponsive *Leishmania donovani* field isolates against reactive oxygen species generated by trivalent antimony. *Parasitology*. 134:1679-87, 2007. PMID: 17612420
- 382.** Mittal MK, Rai S, Ashutosh, Ravinder, Gupta S, Sundar S, Goyal N. Characterization of natural antimony resistance in *leishmania donovani* isolates. *Am J Trop Med Hyg*. 76 :681-8, 2007. PMID: 17426170
- 383.** Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. *J Exp Med*. 204 : 805-17, 2007. PMID: 17389235
- 384.** Samant M, Sahasrabudhe AA, Singh N, Gupta SK, Sundar S, Dube A. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of *Leishmania donovani*. *Parasitology*. 16:1-10, 2007. PMID: 17362540
- 385.** Hide M, Singh R, Kumar B, Banuls AL, Sundar S. A microculture technique for isolating live *Leishmania* parasites from peripheral blood of visceral leishmaniasis patients. *Acta Trop*. 102:197-200, 2007. PMID: 17544353
- 386.** Singh N, Almeida R, Kothari H, Kumar P, Mandal G, Chatterjee M, Venkatachalam S, Govind MK, Mandal SK, Sundar S. Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. *Parasitology*. 134: 777-87, 2007. PMID: 17306059
- 387.** Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in *Leishmania*. *J Med Microbiol*. 56:143-53, 2007. PMID: 17244793
- 388.** Kumar P, Sundar S, Singh N. Degradation of pteridine reductase 1 (PTR1) enzyme during growth phase in the protozoan parasite *Leishmania donovani*. *Exp Parasitol*. 116:182-9, 2007. PMID: 17275814
- 389.** Shrivastava R, Sinha PR, Singh VP, Sundar S. Echocardiographic evaluation of cardiac status in Indian visceral leishmaniasis patients. *Trans R Soc Trop Med Hyg*. 101: 429-32, 2007. PMID: 17049574

- 390.** Attili VS, Singh VP, Sundar S, Mehta H, Negi ML, Gogia A, Raju SH, Rai M. Malignant myelomatous pleural effusion with good response to combination chemotherapy. *J Assoc Physicians India.* 55:595-6,2007. PMID: 18019805
- 391.** Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V. Cure of Antimony Unresponsive Indian Post Kala-azar Dermal Leishmaniasis with Oral Miltefosine. *Tran Roy Soc Trop Med Hyg.* 100: 698-700, 2006. PMID: 16325873
- 392.** Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in *Leishmania donovani* clinical field isolates by modulating drug-induced programmed cell death. *Molecular & Cellular Proteomics.* 6:88-101, 2006. PMID: 17050524
- 393.** Jacquet, D, Boelaert M, Seaman J, Rijal S, Sundar S, Menten J, Magnus, E. Comparative evaluation of freeze dried and liquid antigens in the Direct Agglutination Test for serodiagnosis of Visceral Leishmaniasis (ITMA-DAT/VL). *Trop Med Int Health.* 11:1777-84, 2006. PMID: 17176341
- 394.** Forgher M, Basu R, Theinert S, Roy S, Sundar S, Walden P. Mapping by proteome serology the antigenicity of the parasites in *Leishmania donovani* infection. *PLoSone.* 1: e40, 2006. PMID: 17183669
- 395.** Kothari H, Kumar P, Sundar S, Singh N. Possibility of membrane modification as a mechanism of antimony resistance in *Leishmania donovani*. *Parasitol Int.* 56:77-80, 2006. PMID: 17169604
- 396.** Chakravarty J, Mehta H, Parekh A, Attili SVS, Agrawal NR, Singh SP, Sundar S. Study on Clinico-epidemiological Profile of HIV Patients in Eastern India. *J Assoc Physicians India.* 54: 854-857, 2006. PMID: 17249252
- 397.** Meheus F, Boelaert M, Baltussen R, Sundar S. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. *Trop Med Int Health.* 11:1715-24, 2006. PMID: 17054752
- 398.** Kothari H, Kumar P, Saluja R, Sundar S, Singh N. Translation of open reading frame in kinetoplast DNA minicircles of clinical isolates of *L. donovani*. *Parasitol Res.* 100: 893-7, 2006. PMID: 17047999
- 399.** Singh SP, Reddy DC, Mishra RN, Sundar S. Knowledge, attitude, and practices related to kala-azar in a rural area of Bihar state, India. *Am J Trop Med Hyg.* 75: 505-8, 2006. PMID: 16968930
- 400.** Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M. Amphotericin B Colloidal Dispersion (ABCD) in the Treatment of Indian Visceral Leishmaniasis. *Clin Infect Dis.* 42:608-13, 2006. PMID: 16447104
- 401.** Sundar S, Singh R K, Maurya R S, Kumar B, Chhabra A, Singh V, Rai M. Serological Diagnosis of Indian Visceral Leishmaniasis – Direct Agglutination test

- versus rK39 strip test. *Trans Roy Soc Trop Med Hyg.* 100:533-537, 2006. PMID: 16325874
- 402.** Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. Rapid Noninvasive Diagnosis in Indian Visceral Leishmaniasis: Comparison of Two Strip Test Formats in Detection of Anti-K39 Antibody. *J Clin Microbiol.* 44 :251-3, 2006. PMID: 16390983
- 403.** P´erez-Victoria FJ, S´anchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F. Mechanisms of experimental resistance of *Leishmania* to miltefosine: Implications for clinical use. *Drug Resistance Updates.* 9: 26–39, 2006. PMID: 16814199
- 404.** Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 100: s26-33, 2006. PMID: 12792385
- 405.** Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA. Miltefosine: issues to be addressed in the future. *Trans R Soc Trop Med Hyg.* 100 :S41-4, 2006. PMID: 16750231
- 406.** Singh SP, Reddy DCS, Rai M, Sundar S. Serious underreporting of Visceral Leishmaniasis through passive case reporting in Bihar, India. *Trop Med Intl Health.* 11: 899-905, 2006. PMID: 16772012
- 407.** SV S Attili, Gulati AK, Singh VP, Varma DV, Rai M, Sundar S. Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. *BMC Infectious Diseases .* 6:39, 2006. PMID: 16509972
- 408.** Tripathi P, Ray S, Sundar S, Dube A, Naik S. Identification of *Leishmania donovani* antigens stimulating cellular immune responses in exposed immune individuals. *Clin Exp Immunol.* 143:380–388, 2006. PMID: 16412064
- 409.** Garg R, Shraddha K, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A. *Leishmania donovani*: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis *Vaccine.* 24:2900-9, 2006. PMID: 16448729
- 410.** Kumar R, Pai K, P. Kumar P, Pandey HP, S. Sundar S. Sero-epidemiological study of kala-azar in a village of Varanasi district, India. *Trop Med Int Health.* ;11:41-48, 2006. PMID: 16398754
- 411.** Lockwook DNJ, Sundar S. Serological tests for visceral leishmaniasis - have high sensitivity, but several limitations. (*Editorial*) *BMJ.* 711-2, 2006. PMID: 17023436
- 412.** Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. *Clin Microbiol Rev.* 19: 111-26, 2006. PMID: 16418526

- 413.** Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. *Clin Infect Dis.* 43: 917-24, 2006. PMID: 16941377
- 414.** Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. *Indian J Med Res.* 123: 345-352, 2006. PMID: 16778315
- 415.** Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): Challenges ahead. *Indian J Med Res.* 123: 331-344, 2006. PMID: 16778314
- 416.** Agrawal S, Rai M, Sundar S. Management of visceral leishmaniasis: Indian perspective. *J Postgrad Med.* 51 (suppl): S53-57, 2005. PMID: 16519257
- 417.** Olliaro PL, Guerin PL, Gerstl S, Haaskjold AA, Rottingen J, Sundar S. Treatment options for visceral leishmaniasis: lessons from a review of clinical studies conducted in India during 1980-2004. *Lancet Infect Dis.* 5:763-74, 2005. PMID: 16310148
- 418.** Sundar S, Rai M. The Treatment of Visceral Leishmaniasis. *Expert Opinion Pharmacotherapy.* 6:2821-9, 2005. PMID:16318433
- 419.** Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J. A Phase II Dose-Ranging Study of Sitamaquine for the Treatment of Visceral Leishmaniasis In India. *Amer J Trop Med Hyg.* 73:1005-1011, 2005. (Joint first authors). PMID: 16354802
- 420.** Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB. Sodium stibogluconate resistance in *Leishmania donovani* correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. *Parasitology.* 131: 747-57, 2005. PMID: 16336728
- 421.** Barnett PG, Singh SP, Bern C, Hightower AW, Sundar S. Virgin Soil: The Spread of Visceral Leishmaniasis into Uttar Pradesh, India. *Amer J Trop Med Hyg.* 73 :720-725, 2005. PMID: 16222016
- 422.** Theinert SM, Basu R, Forgher M, Roy S, Sundar S, Walden P. Identification of New Antigens in Visceral Leishmaniasis by Expression Cloning and Immunoblotting with Sera of Kala-Azar Patients from Bihar, India. *Infect Immun.* 73: 7018–21, 2005. PMID: 16177384
- 423.** Ashutosh, Gupta S, Ramesh, Sundar S, Goyal N. Use of *Leishmania donovani* Field Isolates Expressing the Luciferase Reporter Gene in In Vitro Drug Screening. *Antimicrob Agents Chemother.* 49: 3776-83, 2005. PMID: 16131481
- 424.** Sundar S, Agrawal S, Pai K, Chance M, Hommel M. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by latex agglutination test (KAtex). *Amer J Trop Med Hyg.* 73: 269–271, 2005. PMID: 16103587
- 425.** Maurya R, Singh RK, Kumar B, Salotra P, Rai M, Sundar S. Evaluation of PCR in

- the diagnosis of Indian kala-azar and assessment of cure. *J Clin Micro.* 43:3038-41, 2005. PMID: 16000412
- 426.** Manna M, Majumder HK, Sundar S, Bhaduri AN. The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR. *Med Sci Monit.* 11:BR220-227, 2005. PMID: 15990683
- 427.** Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. *Parasitol Res.* 96: 216–223, 2005. PMID: 15868188
- 428.** Attili VS, Singh VP, Rai M, Varma DV, Sundar S. Evaluation of the status of tuberculosis as part of the clinical case definition of AIDS in India. *Postgrad Med J.* 81:404-8, 2005. PMID: 15937209
- 429.** Garg R, Gupta SK, Tripathi P, Naik S, Sundar S, Dube A. Immunostimulatory cellular responses of cured Leishmania infected patients and hamsters against the Integral Membrane Proteins and Non Membranous Soluble Proteins of recent clinical isolate of Leishmania donovani. *Clin Exp Immunol.* 140:149–156, 2005. PMID: 15762886
- 430.** Sundar S, Kumar A. Challenges in the Management of Visceral Leishmaniasis (Editorial). *Indian Ped.* 42: 523-6, 2005. PMID: 15995268
- 431.** Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India (Perspective). *Bull WHO.* 83(5):394-5, 2005. PMID:15976883
- 432.** Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray H W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. *Clin Infect Dis.* 38 : 377-83, 2004. PMID: 14727208
- 433.** Bommer W, Eibl HJ, Engel KR, Kuhlencord A, Sindermann H, Sundar S, Zappel H. Leishmaniasis--oral treatment with hexadecylphosphocholine. *Wien KlinWochenschr.* 116 Suppl 4:24-9, 2004. PMID: 15683039
- 434.** Bandyopadhyay S, Chatterjee M, Das T, Sundar S, Mandal C. Antibodies Directed Against O-Acetylated Sialoglycoconjugates Accelerate Complement Activation in Leishmania donovani Promastigotes. *J Infect Dis.* 190: 2010-9, 2004. PMID: 15529267
- 435.** Bandyopadhyay S, Chatterjee M, Pal S, Waller RF, Sundar S, McConville MJ and Mandal C. Purification, characterization of O-acetylated sialoglycan specific IgM and development of an enzyme linked immunosorbent assay for serodiagnosis of Indian Visceral Leishmaniasis patients. *DiagMicrobiol Inf Dis.* 50:15–24,2004.PMID: 15380274
- 436.** Bandhyopadhyay S, Chatterjee M, Sundar S and Mandal C. Identification of 9-O-acetylated sialoglycans on peripheral blood mononuclear cells in Indian Visceral Leishmaniasis. *Glycoconjugate Journal.* 20: 531–536, 2004. PMID: 15454691

- 437.** Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R. Drug uptake and modulation of drug resistance in *Leishmania* by an aquaglyceroporin. *J Biol Chem.* 279: 31010-7, 2004. PMID: 15138256
- 438.** Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. *Clin Infect Dis.* 38:217-21, 2004. PMID: 14699453
- 439.** Chava AK, Chatterjee M, Sharma V, Sundar S, Mandal C. Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-o-acetylated sialoglycans. *J Infect Dis.* 189:1257-64, 2004. PMID: 15031795
- 440.** Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. *Clin Infect Dis.* 37: 800-4, 2003. PMID: 12955641
- 441.** Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala-azar field isolates. *J Infect Dis.* 188: 600-7, 2003. PMID: 12898450
- 442.** Sundar S. Diagnosis of kala-azar – An important stride Editorial. *J Assoc Physicians India.* 51: 753-5, 2003. PMID: 14651132
- 443.** Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. *Pediatr Infect Dis J.* 22: 434-8, 2003. PMID: 12792385
- 444.** Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of *Leishmania donovani* to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. *Antimicrob Agents Chemother.* 47: 1529-35, 2003. PMID: 12709318
- 445.** Davies CR, Kaye P, Croft SL, Sundar S 2003. Leishmaniasis: new approaches to disease control. *BMJ.* 326(7385):377-82, 2003. PMID: 12586674
- 446.** Sundar S, Benjamin B. Diagnosis and treatment of Indian visceral leishmaniasis. *J Assoc Physicians India.* 51:195-201, 2003. PMID: 12725267
- 447.** Sundar S. Indian kala-azar – Better tools needed for diagnosis and treatment. *J Postgrad Med.* 49: 29-30, 2003. PMID: 12865568
- 448.** Sundar S, Rai M. Advances in the treatment of leishmaniasis. *Curr Opin Infect Dis.* 15: 593-8, 2002. PMID: 12821836
- 449.** Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. *Clin Diagn Lab Immunol.* 9: 951-8, 2002. PMID: 12204943
- 450.** Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD 2002. Visceral leishmaniasis: current status of control, diagnosis, and

- treatment, and a proposed research and development agenda. *Lancet Infect Dis.* 2(8):494-501, 2002. PMID: 12150849
- 451.** Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. *N Engl J Med.* 347: 1739-46, 2002. PMID: 12792385
- 452.** Kumar P, Pai K, Pandey HP, Sundar S. NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. *J Med Microbiol.* 51: 832-6, 2002. PMID: 12435061
- 453.** Eidsmo L, Wolday D, Berhe N, Sabri F, Satti I, El Hassan AM, Sundar S, Chiodi F, Akuffo H. Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. *Clin Exp Immunol.* 130: 307-13, 2002. PMID: 12390320
- 454.** Chava AK, Chatterjee M, Sundar S, Mandal C. Development of an assay for quantification of linkage-specific O-acetylated sialoglycans on erythrocytes its application in Indian visceral leishmaniasis. *J Immunol Methods.* 270: 1-10, 2002. PMID: 12379333
- 455.** Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S 2002. Immunoblot analysis of the humoral immune response to *Leishmania donovani* polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. *Clin Diagn Lab Immunol.* 9: 1119-23, 2002. PMID: 12204969
- 456.** Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, Berman JD, Murray HW. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. *Clin Infect Dis.* 35: 581-6, 2002. PMID: 12173133
- 457.** Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. *Am J Trop Med Hyg.* 66: 143-6, 2002. PMID: 12135284
- 458.** Sundar S, Pai K, Sahu M, Kumar V, Murray HW. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. *Ann Trop Med Parasitol.* 96 : 19-23, 2002. PMID: 11989529
- 459.** Singh N, Singh RT, Sundar S. Identification of a gene linked to drug resistance in field isolates of *Leishmania donovani*. *Ann Trop Med Parasitol.* 96: 839-41, 2002. PMID: 12625940
- 460.** Rai M, Srinivasan A, Sundar S, Singh VP. Cyclosporine-induced reversible pure motor spastic paraparesis in a patient with aplastic anaemia. *J Assoc Physicians India.* 50: 133-7, 2002. .PMID: 12568232
- 461.** Singh VP, Rai M, Shukla J, Sundar S, Usha. Chronic lymphocytic leukaemia terminating into plasma cell leukemia. *J Assoc Physician India.* 50: 840-1, 2002. PMID: 12240859

- 462.** Singh VP, Khanna A, Rai M, Sundar S, Shukla PK, Naresh T, Shukla J. Non-Hodgkin's lymphoma with pure red cell aplasia. *J Assoc Physicians India.* 49: 1123-4, 2001. PMID: 11868873
- 463.** Pai K, Sundar S. A simple and inexpensive "cell dissociation sieve-tissue grinder" apparatus. *Indian J Exp Biol.* 39: 483-4, 2001. PMID: 11510135
- 464.** Sundar S. Liposomal amphotericin B Letter. *Lancet .* 357: 801-2,2001.PMID: 11253992
- 465.** Rai M, Singh VP, Shukla J, Sundar S, Jha VC. Low dose cyclosporine-a therapy in severe aplastic anaemia. *J Assoc Physicians India.* 49: 966-9, 2001. PMID: 11848327
- 466.** Carter KC, Mullen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of *Leishmania donovani*. *Antimicrob Agents Chemother.* 45: 3555-9, 2001. PMID: 11709339
- 467.** Salotra P, Sreenivas G, Ramesh V, Sundar S. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. *Br J Dermatol.* 145: 630-2, 2001. PMID: 11703291
- 468.** Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. *Clin Diagn Lab Immunol.* 8: 1220-4, 2001. PMID: 11687466
- 469.** Sundar S, Pai K, Kumar R, Pathak-Tripathi K, Gam AA, Ray M, Kenney RT. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. *Am J Trop Med Hyg.* 65: 193-6, 2001. PMID: 11561703
- 470.** Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. *BMJ.* 323: 419-22, 2001. PMID: 11520836
- 471.** Kumar R, Pai K, Sundar S. Reactive oxygen intermediates, nitrite and IFN-(in Indian visceral leishmaniasis. *Clin Exp Immunol.* 124 : 262-5, 2001. PMID: 11422203
- 472.** Sundar S. Treatment of visceral leishmaniasis. *Med Microbiol Immunol Berl.* 190: 89-92, 2001. .PMID: 11770119
- 473.** Sundar S. Drug resistance in Indian visceral leishmaniasis. *Trop Med Int Health.* 6: 849-54, 2001. PMID: 11703838
- 474.** Mandal AK, Singh VP, Gulati AK, Sundar S, Mohapatra SC, Gupta KK, Matah SC, Rai M. Prevalence of human immunodeficiency virus infection in and around Varanasi, Uttar Pradesh, India. *J Assoc Physicians India.* 48 :288-9, 2000. PMID: 11229111
- 475.** Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P,

- Murray HW. Short-course of oral miltefosine for treatment of visceral leishmaniasis. *Clin Infect Dis*. 31: 1110-3, 2000. PMID: 11049800
- 476.** Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. *Clin Infect Dis*. 31: 1104-7, 2000. PMID: 11049798
- 477.** Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. *Trans R Soc Trop Med Hyg*. 94: 200-4, 2000. PMID: 10897369
- 478.** Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. *J Assoc Physicians India*. 47: 186-8, 1999. PMID: 10999086
- 479.** Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. *Ann Trop Med Parasitol*. 93: 589-97, 1999. PMID: 10707104
- 480.** Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. *N Engl J Med*. 341: 1795-800, 1999. Shared first authorship. PMID: 10588964
- 481.** Singh N, Curran MD, Rastogi AK, Middleton D, Sundar S. Diagnostic PCR with *Leishmania donovani* specificity using sequences from the variable region of kinetoplast minicircle DNA. *Trop Med Int Health*. 4: 448-53, 1999. PMID: 10444321
- 482.** Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of *Leishmania donovani*. *J Infect Dis*. 180: 564-7, 1999. PMID: 10395884
- 483.** Chatterjee M, Jaffe CL, Sundar S, Basu D, Sen S, Mandal C. Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India. *Clin Diagn Lab Immunol*. 6: 550-4, 1999. PMID: 10391861
- 484.** Kumar R, Kumar P, Chowdhary RK, Pai K, Mishra CP, Kumar K, Pandey HP, Singh VP, Sundar S. Kala-azar epidemic in Varanasi district, India. *Bull World Health Organ*. 77: 371-4, 1999. PMID: 10361752
- 485.** Chatterjee M, Sharma V, Mandal C, Sundar S, Sen S. Identification of antibodies directed against O-acetylated sialic acids in visceral leishmaniasis: its diagnostic and prognostic role. *Glycoconj J*. 15: 1141-7, 1998. PMID: 10372969
- 486.** Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-

- unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. *Ann Trop Med Parasitol.* 92(7):755-64, 1998.PMID: 9924533
487. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. *Lancet.* 352: 1821-3, 1998.PMID: 9851383
488. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP. *Am J Trop Med Hyg.* 59: 139-43, 1998. PMID: 9684642
489. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. *J Infect Dis.* 177: 815-8, 1998. PMID: 9498473
490. Sundar S, Reed SG, Singh VP, Kumar PC, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. *Lancet.* 351: 563-5, 1998. PMID: 9492776
491. Sundar S, Murray HW. Costs of Amphotericin B Lipid Complex for kala-azar Letter. *Ann Intern Med.* 128: 26, 1998. PMID: 9471948
492. Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, Murray H. Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar Letter. *Clin Infect Dis.* 27: 215-6, 1998.PMID: 9675482
493. Sundar S, Singh VP, Dube RK, Dube B, Agrawal NR. Chronic neutrophilic leukaemia:a case report. *J Assoc Physicians India.* 36: 389-90, 1998. PMID: 3182716
494. Singh S, Sundar S, Singh VP. Leishmaniasis: recent advances in treatment Letter. *J Am Acad Dermatol.* 37: 512-3, 1997. PMID: 9308581
495. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. *J Infect Dis.* 176: 1117-9, 1997. PMID: 9333181
496. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G. Antibody response against a *Leishmania donovani* amastigote-stage-specific protein in patients with visceral leishmaniasis. *Clin Diagn Lab Immunol.* 4: 530-5, 1997. PMID: 9302200
497. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. *Ann Intern Med.* 15 127: 133-7, 1997. PMID: 9230003
498. Singh N, Sundar S, Williams F, Curran MD, Rastogi A, Agrawal S, Middleton D. Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. *Trop Med Int Health.* 2 :468-71, 1997. PMID: 9217702
499. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW. Circulating T helper 1

- Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. *Am J Trop Med Hyg.* 56: 522-5, 1997. PMID: 9180602
- 500.** Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. *J Infect Dis.* 173: 762-5, 1996. PMID: 8627049
- 501.** Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole Letter. *Lancet.* 348: 614, 1996. PMID: 8774589
- 502.** Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. *J Infect Dis.* 172: 1627-9, 1995. PMID: 7594733
- 503.** Singh S, Singh R, Sundar S. Failure of ketoconazole in oriental sore in India. *J Chemother.Suppl* 4:202-3, 1995. PMID: 8904156
- 504.** Dube B, Arora A, Singh VP, Kumar K, Sundar S. Plateletfunction studies in Indian kala-azar. *J Trop Med Hyg.* 98: 166-8, 1995. PMID: 7783273
- 505.** Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection:accelerated response using interferon-gamma in visceral leishmaniasis. *J Infect Dis.* 171: 992-6, 1995. PMID: 7706829
- 506.** Singh S, Singh R, Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. *Int J Dermatol.* 34: 120-1, 1995. PMID: 7737771
- 507.** Sundar S, Murray HW 1995. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. *J Assoc Physicians India.* 43(5):348-50, 1995. PMID: 9081967
- 508.** Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. *J Infect Dis.*170: 659-62, 1994. PMID: 8077725
- 509.** Singh S, Sundar S. Treatment of post-kala-azar dermal leishmaniasis Letter. *Int J Dermatol.* 34: 668-9, 1995. PMID: 7591476
- 510.** Vinayak VK, Mahajan D, Sobti RC, Singla N, Sundar S. Anti-66 kDa antileishmanial antibodies as specific immunodiagnostic probe for visceral leishmaniasis. *Indian J Med Res.* 99: 109-14, 1994. PMID: 8063345
- 511.** Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, Mahapatra TM, Singh VP. Clinicoepidemiological study of drug resistance in Indian kala-azar. *BMJ.* 308: 307, 1994. PMID: 8124119
- 512.** Singh VP, Sundar S, Kumar K, Shukla J, Dube B 1994. Plasma cell leukemia--report on two cases. *J Assoc Physicians India.* 42: 824-5, 1994. PMID: 7876056
- 513.** Singh VP, Sundar S, Kumar K, Shukla J, Dube B. Down's syndrome with acute myeloid leukemia. *J Assoc Physicians India.* 42 :621, 1994. PMID: 7868556

- 514.** Singh S, Sundar S. Toxicity of pentavalent antimony Letter. *J Assoc Physicians India.* 42: 755, 1994. PMID: 7741886
- 515.** Singh VP, Sundar S, Kumar K, Shukla J, Dube B. "Prolymphocytoid" transformation of chronic lymphocytic leukemia. *J Assoc Physicians India.* 41: 312, 1993. PMID: 8300471
- 516.** Singh VP, Sundar S, Kumar K, Dube B, Dube RK. Acquired pure red cell aplasia: is chloroquine a culprit? *J Assoc Physicians India.* 41: 607, 1993. PMID: 8307924
- 517.** Singla N, Singh GS, Sundar S, Vinayak VK. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. *Trans R Soc Trop Med Hyg.* 87: 276-8, 1993. PMID: 8236390
- 518.** Sundar S, Moorleedhur-Singh GS, Dube B, Singh VP, Kumar K. Danazol in Indian haemophiliacs. *J Assoc Physicians India.* 41: 23-5, 1993. PMID: 8340322
- 519.** Sundar S, Moorleedursingh GS, Kumar K, Dube B, Singh VP. Danazol therapy in chronic idiopathic thrombocytopenic purpura. *J Assoc Physicians India.* 40: 350-1, 1992. PMID: 1484008
- 520.** Gupta RK, Bhattacharya SK, Sundar S, Kumar K, Kachhawaha JS, Sen PC. A correlative study of serum zinc and in vivo cell mediated immune status in rheumatic heart disease. *Acta Cardiol.* 47: 297-304, 1992. PMID: 1523910
- 521.** Sundar S, Singh VP. Chronic myeloid leukaemia with massive lymphadenopathy. *J Assoc Physicians India.* 40: 285, 1992. PMID: 1452552
- 522.** Sundar S, Kumar K, Singh VP, Mahopatra TM. Diagnostic lag period in kala-azar: test for early diagnosis needed Letter. *J Assoc Physicians India.* 39: 651, 1991. PMID: 1814888
- 523.** Bhattacharya SK, Gupta RK, Kumar K, Sundar S, Kachhawaha JS, Sen PC. Zinc in rheumatic heart disease--role in immunopathogenesis? *J Assoc Physicians India.* 39: 428, 1991. PMID: 1960175
- 524.** Sundar S, Mall RK, Dube B, Singh VP. Antithrombin III in liver disorders. *J Assoc Physicians India.* 39: 522-4, 1991. PMID: 1800493
- 525.** Sundar S, Rajan AG, Somani PN, Kumar K 1991. The effects of antihypertensive agents on the quality of life in Indian hypertensives. *Acta Cardiol.* 46: 227-35, 1991. PMID: 2048369
- 526.** Singh V, Bhattacharya SK, Sundar S, Kachhawaha JS. Serum and urinary copper in acute hepatic encephalopathy. *J Assoc Physicians India.* 38: 467-9, 1990. PMID: 2292550
- 527.** Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis (Letter). *Lancet.* 336: 1582-3, 1990. PMID: 1979393

- 528.** Singh DS, Gupta SS, Gupta R, Gambhir IS, Sundar S, Agrawal AK. Bleeding from gastric ulcer in portal hypertension Letter. *J Assoc Physicians India.* 38:5 18-9, 1990. PMID: 2292570
- 529.** Gupta SS, Gupta R, Gambhir IS, Sundar S, Agrawal AK, Singh DS. Inferior venacaval obstruction following burns (Letter). *J Assoc Physicians India.* 38: 243, 1990. PMID: 2391308
- 530.** Singh SB, Singh VP, Gupta S, Gupta RM, Sundar S. Tropical myositis. A clinical immunological and histopathological study. *J Assoc Physicians India.* 37: 561-3, 1989. PMID: 2632556
- 531.** Singh V, Bhattacharya SK, Sundar S, Kachhawaha JS. Zinc levels in the cerebrospinal fluid, serum & urine in acute hepatic encephalopathy. *Indian J Med Res.* 87: 594-9, 1988. PMID: 3240938
- 532.** Sundar S. Prostacyclin in extracted plasma of essential hypertensives. *Acta Cardiol.* 42: 135-9, 1987. PMID: 3300116
- 533.** Agarwal SK, Sundar S. Which regimen to be used in retreatment cases of pulmonary tuberculosis? (Letter) *J Assoc Physicians India.* 34: 227, 1986. PMID: 3733660
- 534.** Singh DS, Sundar S and Tripathi KK. Tricyclic antidepressant therapy in duodenal ulcer. *J Indian Med Assoc.* 85: 265-7, 1987. PMID: 3450741
- 535.** Bhattacharya SK, Sundar S. Unusual cases of herpes zoster involving cranial nerves (Letter). *J Assoc Physicians India.* 34: 161, 1984. PMID: 3711014
- 536.** Agarwal SK, Sundar S. Empyema (Letter). *J Assoc Physicians India.* 33: 681-2, 1985. PMID: 4093377
- 537.** Sundar S, Bhattacharya SK, Chowdhary R, Dube B. Polymorphocytic leukaemia. *J Indian Med Assoc.* 83: 244-5, 1985. PMID: 3866798
- 538.** Bhattacharya SK, Sundar S, Sabharwal NC. Massive splenomegaly (regressing with therapy) in amoebic liver abscess. *J Indian Med Assoc.* 83: 202-4, 1985. PMID: 2867115
- 539.** Agarwal SK, Sundar S. Drip method in empyema thoracis (Letter). *J Assoc Physicians India.* 33: 250, 1985. PMID: 4044490
- 540.** Agarwal K, Roy DC, Matah SC, Sundar S. Retreatment of pulmonary tuberculosis. *J Assoc Physicians India.* 33: 814-6, 1985. PMID: 3837007
- 541.** Sundar S, Sachdev KK, Vaish SK, Bhattacharya SK, Singh VP, Agarwal SK. Potassium supplementation in essential hypertension--a double blind placebo controlled study. *J Assoc Physicians India.* 33: 776-7, 1985. PMID: 3915499
- 542.** Agrawal NR, Singh V, Bhattacharya SK, Sundar S, Tiwari P. Prognostic

- significance of zinc in pregnancy with hepatitis. *Asia Oceania J ObstetGynaecol.* 11: 589-91, 1985. PMID: 3833161
- 543.** Pandey SP, Bhattacharya SK, Sundar S. Zinc in rheumatoid arthritis. *Indian J Med Res.* 81: 618-20, 1985. PMID: 4054969
- 544.** Agarwal SK, Roy DC, Sundar S, Matah SC. Short course intermittent chemotherapy in pulmonary tuberculosis. *J Assoc Physicians India.* 33: 281-2, 1985. PMID: 4030678
- 545.** Singh DS, Seecatt JS, Sundar S, Rai AK, Dube RK, Gupta JP, Srivastava PK. Platelets in hepatic disorders. *J Assoc Physicians India.* 33: 453-5, 1985. PMID: 4055662
- 546.** Sundar S, Kapil R, Dube B, Vaish SK. Antithrombin-III activity in ischaemic heart disease. *Indian Heart J.* 36: 46-9, 1984. PMID: 6423518
- 547.** Sundar S, Sinha AK, Vaish SK. Blood carboxyhaemoglobin: a better index of smoking. *J Assoc Physicians India.* 32: 803-4, 1984. PMID: 6511771
- 548.** Sundar S, Shyam B, Gulathi AK, Somani PN. Coxsackie--a viral carditis in eastern India. *J Assoc Physicians India.* 32: 501-3, 1984. PMID: 6096350
- 549.** Sundar S, Singh VP, Burma DP, Vaish SK. Digoxin induced arrhythmias and electrolytes. *Indian Heart J.* 36: 104-6, 1984. PMID: 6724624
- 550.** Sundar S, Agrawal SK, Singh VP, Bhattacharya SK, Udupa KN, Vaish SK. Role of yoga in management of essential hypertension. *Acta Cardiol.* 39: 203-8, 1984. PMID: 6331698
- 551.** Sundar S. Is bradycardia dependent intermittent bundle branch block digoxin induced? (Letter) *J Assoc Physicians India.* 32: 762, 1984. PMID: 6511761
- 552.** Sundar S, Avasthey P, Burma DP, Vaish SK. Intermittent right bundle branch block due to digoxin toxicity--a rare electrocardiographic manifestation. *Indian Heart J.* 35: 238-40, 1983. PMID: 6629406
- 553.** Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. *Acta Cardiol.* 38: 115-23, 1983. PMID: 6603084
- 554.** Bhattacharya SK, Sundar S, Gupta PR, Singh TJ, Vaish SK. Scleredema – Some unusual features case report. *Indian J Derm Ven Lep.* 48: 365-369, 1982. PMID: 28193923

**TEXT BOOKS / MONOGRAPHS / CHAPTERS IN THE BOOKS
PUBLISHED**

- 555.** B Singh, AK Kushwaha, SS Singh, S Sundar. Functionalized Graphene Modified Electrochemical Sensors for Toxic Chemicals Graphene-Based Electrochemical Sensors for Toxic Chemicals. In Graphene-Based Electrochemical Sensors for Toxic Chemicals (Eds A Pandikumar, P Rameshkumar). Material Research Forum LLC, Millersville, PA USA. 2020, 82: 25-60.
- 556.** Gedda MR, Singh OP, Srivastava ON, Sundar S. Therapeutic Leishmaniasis: Recent Advancement and Developments in Nanomedicines. In Singh S, P. K. Maurya (eds.), Nanotechnology in Modern Animal Biotechnology, Springer Nature Singapore Pte Ltd. 2019 https://doi.org/10.1007/978-981-13-6004-6_6
- 557.** Sundar S, Chakravarty J. Leishmaniasis. In PG Text Book of Pediatrics (Eds. Gupta P, Menon PSN, Ramji S, Lodha R) 2nd Edition Jaypee Brothers New Delhi. pp 1478-84, 2018.
- 558.** Sundar S. Leishmaniasis. In *Harrison's Principles of Internal Medicine* (Eds. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Joscalszo J.) 19th Ed. McGraw Hill Companies Inc. New York. pp 1387-94, 2015. 20th Ed. Pp 1594-1601, 2018
- 559.** Kronman M.P., Smith S., Balasubramanian S., Alagarsamy P., Gupta A., Prabhu S., Singh A., Mishra O.P., **Sundar S.**, Singh V. and Ranbir L. Infectious Diseases in Nelson Essentials of Pediatrics 1st South Asia Edition (Editors Marc dante K.J. and Kliegman R.M.), Elsevier RELX India Pvt. Ltd. ; New Delhi, 2016 : Pp. 303 – 422.
- 560.** Sundar S, Chakravarty J: Leishmaniasis – In Postgraduate Text Book of Paediatrics (editor Gupta P) pp 1237-1243, 2015.
- 561.** Sundar S, Chakravarty J. Mechanism of Drug Resistance in Visceral Leishmaniasis. In *Leishmania: Current Biology and Control* (Eds. Adak S and Datta R). Caister Academic Press. Poole, UK. ISBN: 978-1-908230-52-2, 2015.
- 562.** Boelaert M, Sundar S. Leishmaniasis. In *Manson's Tropical Diseases* (Eds. Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ). 23rd Ed. Elsevier Saunders pp 631-51, 2014.
- 563.** Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dube A, Shrivastav ON, Sundar S. Nanonization Increases the Antileishmanial Efficacy of Amphotericin B: An Ex Vivo Approach. In R. Adhikari and S. Thapa (eds.), Infectious Diseases and Nanomedicine II, Advances in Experimental Medicine and Biology 808, Springer India, New Delhi. pp 77-91, 2014.
- 564.** Sundar S, Chakravarty J. Visceral Leishmaniasis. In Drug Resistance in Leishmania Parasites, (Ed. Ponte Sucre A) Springer-Verlag, Vienna. pp. 183-98, 2013.
- 565.** Sundar S, Chakravarty J. Leishmaniasis: Challenges in the Control and Eradication. In Challenges in Infectious Diseases (Ed. Fong IW) Springer New York.

pp 247-264, 2013.

- 566.** Sundar S. Leishmaniasis. In *Harrison's Principles of Internal Medicine* (Eds. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Joscalszo J. 18th Ed. McGraw Hill Companies Inc. New York. pp 1709-16, 2012.
- 567.** Sundar S. Leishmaniasis. In *API Textbook of Medicine* (Eds. Munjal YP, Sharma SK, Agarwal AK, Gupta P, Kamath SA, Nadkar MY, Singhal RK, Sundar S, Varma S) 9th Edition. *Association of Physicians of India*, Mumbai. pp 1188-91, 2012.
- 568.** Sundar S, Arora R. Research on treatment of visceral leishmaniasis – Past, Present and Future. In *Kala-azar – Emerging perspectives and prospects in South Asia*. (Ed. HP Thakur) Mittal Publications; New Delhi pp 125 – 154, 2011.
- 569.** Sundar S, Agarwal D. A therapeutic strategy for treating visceral leishmaniasis in regions with drug resistance. In *Kala-azar in South Asia* (Eds Jha TK, Noiri E) Springer, London pp 35-46, 2011.
- 570.** Sundar S, Agarwal D. Antiretroviral. In *Fundamentals of Global HIV Medicine* (Eds. Temesgen Z, Amoroso A, Gilliam B, Goosby EP, Orenstein R) IHL Press, College Park, USA. Ch 8: 77-83, 2010.
- 571.** Sundar S, Atilli VSS. Gastrointestinal complications of HIV Infection. In *Fundamentals of Global HIV Medicine* (Eds. Temesgen Z, Amoroso A, Gilliam B, Goosby EP, Orenstein R) IHL Press, College Park, USA. Ch 29: 257-66, 2010.
- 572.** Sundar S, Atilli VSS. Hepatobiliary complications of HIV Infection. In *Fundamentals of Global HIV Medicine* (Eds. Temesgen Z, Amoroso A, Gilliam B, Goosby EP, Orenstein R) IHL Press, College Park, USA. Ch 30: 267-75, 2010.
- 573.** Cockrell DH, Sundar S, Angus B. Infectious disease. In *Davidson's Principles and Practice of Medicine* (Eds. Colledge N, Walker B, Ralston S) 21th Ed. Elsevier Publishers, Edinburgh, UK. Ch 13: 289-381, 2009.
- 574.** Sundar S. An Indian farmer with a high fever. In *Davidson's clinical cases*. (Eds Strachan MWJ, Sharma SK, Hunter JAA) First Ed. Publishers, Edinburgh, UK. p. 56-9, 2008.
- 575.** Sundar S, Rai M. Parasitic Drug Resistance – Clinical :Leishmania. In *Antimicrobial Drug Resistance* (Eds – Mayers DL, Sobel JD, Ouellette M, Lerner s) 1st Ed Humana Press. pp 1075-86, 2008.
- 576.** Sundar S. Leishmaniasis. In *API Text Book of Medicine* (Ed. S Shah). Association of Physicians of India, Mumbai. 8th Edition Chapter 62, pp. 130-133, 2008.
- 577.** M. Hide,1 B. Bucheton, S. Kamhawi, R. Bras-Gonçalves, S. Sundar, J.-L. Lemesre, A.-L. Banuls. Understanding Human Leishmaniasis: The Need for an Integrated Approach. In *Encyclopedia of Infectious Diseases: Modern Methodologies*, (Ed. M.Tibayrenc). John Wiley & Sons, Inc, New York. Chapter 6, pp. 87-123, 2007.

- 578.** Sundar S, D. Agrawal and J. Chakravarty Leishmaniasis - Where Are We. *In International Proceedings Tropical Medicine and International Health* (5th Cong), (Ed. Boeree MJ) Medimond, Amsterdam. 135-42, 2007.
- 579.** Todd A, Lockwood D, Sundar S. Infectious disease. *In Davidson's Principles and Practice of Medicine* (Eds. Boon N, Colledge N, Walker B, Hunter J) 20th Ed. Elsevier Publishers, Edinburgh, UK. P.283-376, 2006.
- 580.** Todd A, Sundar S, Lockwood. D Principles of Infectious disease *In Davidson's Principles and Practice of Medicine* (Eds. Boon N, Colledge N, Walker B, Hunter J) 20th Ed. Elsevier Publishers, Edinburgh, UK. P.129-158, 2006.
- 581.** Sundar S. Drug Trials. *In Scientific Working Group Report on Leishmaniasis.* TDR/WHO 71-73, 2004.
- 582.** Sundar S. Leishmaniasis. *In Conn's Current Therapy* (Eds. Rakel RE, Bope ET). WB Saunders, Philadelphia, USA; pp90-93 2002.

a. **BOOKS EDITED) & ARTICLES PUBLISHED IN SEMINARS, SYMPOSIA, CONFERENCE PROCEEDINGS/ UPDATES**

B. BOOKS EDITED

- 583.** “Singh, O. P., Kumar, R., Petersen, C., Sundar, S., Le Rutte, E., eds. (2022). *Leishmaniasis: Control and Elimination*. Lausanne: Frontiers Media SA. doi: 10.3389/978-2-88974-345-2”.
- 584.** Sundar S. Editor. *API Textbook of Medicine* (Eds. Munjal YP, Sharma SK, Agarwal AK, Gupta P, Kamath SA, Nadkar MY, Singhal RK, Sundar S, Varma S) 9th and 10th Edition. Association of Physicians of India, Mumbai, 2012.
- 585.** Sundar S. (Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). *Medicine for Practising Physicians*. Shankar Press, Varanasi, 2007 (conference proceedings)
- 586.** Sundar S. *Indian Kala-azar*. Khandelwal Offsets, Varanasi, 1996. (conference proceedings)
- 587.** Singh DS, Singh NK, Sundar S. *Medicine Update (Vol IV)*. Jauhari Printers, Varanasi, 1994. (conference proceedings)
- 588.** Sundar S. *Kala-azar Elimination in India*. Ch 101 in *Medicine Update* (Ed. Gupta P). ISBN 978-81-935342-6-7. Vol 28, pp. 607-9, 2018.
- 589.** Sundar S, Chakravarty J. *Management of Kala-Azar – from Bench to Bedside*. *Medicine Update 2017* (Ed. Bansode BR, Muruganathan A) *Assoc Physicians India*, Mumbai . 27: 42-44, 2017.

- 590.** Sundar S, Singh A. Kala-azar – An Overview. In *Clinical Medicine* (1st Ed., Editor – Rewari BB). Jaypee Brothers Medical Publishers, New Delhi. ISBN 978-93-5090-629-3 pp 225-30, 2014.
- 591.** Sundar S&Chakravarty J. What is next in Leishmaniasis? In: Panja M (ed) *Postgraduate Medicine* (XXVII), 542-49, 2013.
- 592.** Sundar S, Singh A, Chakravarty J. Leishmaniasis: Current Burden and Trends. *Medicine Update* (Ed. Kamath S). *Assoc Physicians India*, Mumbai. 22: 24-28, 2012.
- 593.** Sundar S, Chakravarty J. Therapeutic strategies in kala-azar: Status 2011. *Medicine Update* (Ed. Banerjee AK) *Assoc Physicians India*, Mumbai. 21: 479-82, 2011.
- 594.** Sundar S. Management of Kala-Azar – An Update. *Proceeding of International CME on Tropical & Infectious Diseases*, Kolkata. pp 62-70, 2011.
- 595.** Sundar S, Singh A, Shah A. Visceral Leishmaniasis – Current Scenario. In *Medicine Update* (Ed. Rao MS). Vol 20 pp856-60, 2010.
- 596.** Sundar S. Infections Transmitted from Donor to Recipient following Organ Transplantation in *Medicine Update-2009* (Eds. Agrawal AK, Jain DG, Yadav P), *Assoc Physicians India*, Mumbai. 19: 796-801, 2009.
- 597.** Sundar S, Chakravarty J. Antimicrobial resistance in kala-azar. In *Antimicrobial Resistance – The Modern Epidemic* (Eds. Raghunath D, Nagaraja V, Durga Rao C). Pub. Macmillan Publishers India Ltd, Delhi. pp.73-81, 2009.
- 598.** Gidwani K, Rai M, Chakravarty J, Sundar S. Leishmania Vaccine. In *Adult Immunization* (Eds. Sharma SK, Singal RK, Agarwal AK). Pub. *Association of Physicians of India*, Mumbai. pp. 111-5, 2009.
- 599.** Sundar S, Chakravarty J. Anaemia in Visceral Leishmaniasis. In *Anaemia in Tropics* (Ed. N Mukherjee) Pub: *Indian College of Physicians*, Mumbai. pp. 130-34, 2009.
- 600.** Sundar S. Drug Development and Toxicity. In *Molecular and Physiological Aspects of Toxicology* (Ed. K Shah) Publisher Mahila Mahavidyalaya, BHU, Varanasi 1st Ed pp 88-92, 2009.
- 601.** Chakravarty J, A Singh, Rai M, Sundar S. Liposomal drug delivery system from laboratory to clinic. In *Medicine Update* (Ed. AK Agarwal). Vol 19 pp122-7, 2009.
- 602.** Chakravarty J, Rai VK, Rai M, Sundar S. Antileishmanial Resistance – Reasons and Remedies. In *Medicine Update* (Ed. SK Bichile). Vol 18 pp486-90, 2008.
- 603.** Rai M, Padey S, Chakravarty J, Sundar S. Nosocomial Infection – Prevention and Management. In *Postgraduate Medicine* (Ed. YP Munjal). Vol 22 pp 77-86, 2008.
- 604.** Chakravarty J, Agarwal D, Chaubey L, Trivedi S, Rai M, Sundar S. Evaluation

- of HIV patients at primary care level. Section 3: HIV/AIDS. *In Medicine for Practising Physicians*. Sundar S(Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. p 55-9, 2007.
- 605.** Chakravarty J, Agarwal D, Chaubey L, Trivedi S, Rai M, Sundar S. Management of antiretroviral therapy. Section 3: HIV/AIDS. *In Medicine for Practising Physicians*. Sundar S(Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. p 60-4, 2007.
- 606.** Agarwal D, Chaubey L, Trivedi S, Chakravarty J, Rai M, Sundar S. HIV. In children. Section 3: HIV/AIDS in *Medicine for Practising Physicians*. Sundar S (Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. p 65-9, 2007.
- 607.** Singh A, Chakravarty J, Agarwal D, Chaubey L, Rai M, Sundar S. Postexposure Prophylaxis. Section 3: HIV/AIDS. In *Medicine for Practising Physicians*. Sundar S (Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. 2007, p 73-7.
- 608.** Rai M, Chakravarty J, Sundar S. How should one choose the first-line drug for hypertension. Section 2: Cardio-Diabetology. In *Medicine for Practising Physicians*. Sundar S(Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. p31-3, 2007.
- 609.** Chaubey L, Chakravarty J, Agarwal D, Trivedi S, Rai M, Sundar S. HIV in Pregnancy. Section 3: HIV/AIDS . In *Medicine for Practising Physicians*. Sundar S (Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. (Proceeding/ UPICON Update), p. 70-2, 2007.
- 610.** Rajni, Kumar D, Chakravarty J, Sundar S. Management of Sepsis : Current Trends. Section 6: Miscellaneous. In *Medicine for Practising Physicians*. Sundar S (Editor-in-chief). (Eds Rai M, Kumar K, Chakravarty J). Shankar Press, Varanasi. (Proceeding/ UPICON Update), p. 124-31, 2007.
- 611.** Sundar S. Update of antibiotic therapy – where and when? *Current Med J India*. 12: 47-57, 2007.
- 612.** Chakravarty J, Agrawal D, Agrawal N, Rai M, Sundar S. Visceral leishmaniasis: Current concepts in management. (Ed Singal RK, Jain DG) Jaypee Publishers, New Delhi. 16 : 533-7, 2007.
- 613.** Rai M, Goyal P, Chakravarty J, Sundar S. Immune Reconstitution Inflammatory Syndrome. *Medicine Update* (Ed Singal RK, Jain DG) Jaypee Publishers, New Delhi. 16 : 652-5, 2007.
- 614.** Sundar S, Rai VK, Chakravarty J. Tropical infection in the intensive care unit. In *Medicine Update* (Editor Agarwal N) Proceedings of UPICON 2006; Jhansi. pp. 177-83, 2006.
- 615.** Sundar S, Chakravarty J, Chauhan V. Kala-azar : Current Perspective. In *Clinical*

Medicine Update - 2006 (Editors Agarwal AK, Jain DG). Jaypee Publishers, New Delhi. pp.420-4, 2006.

- 616.** Sundar S, Agrawal D, Chakravarty J. Treatment of HIV infection. In *Medicine Update* UPICON 2005 (Ed. Mishra M, Mittal M) Badal Offset, Gorakhpur. pp. 83-100, 2005.
- 617.** Sundar S. Treatment of Kala-azar. In *Trends and Research in Leishmaniasis with particular reference to Kala Azar* (Eds. Raghunath D, Nayak R). Tata McGraw-Hill Publishing Co Ltd. New Delhi. pp. 157-165, 2005.
- 618.** Chava AK, Chatterjee M, Sundar S, Mandal C. O-acetylated Sialoglycoconjugates: Novel Biomarkers on Erythrocytes for Diagnosis and Prognosis of Indian Visceral Leishmaniasis and its Biological Role. In *Trends and Research in Leishmaniasis with particular reference to Kala Azar* (Eds. Raghunath D, Nayak R). Tata McGraw-Hill Publishing Co Ltd. New Delhi. pp. 223-243, 2005.
- 619.** Sundar S, Rai M, Chakravarty J, Agrawal S. Prevention of antibiotic resistance/antibiotic misuse-abuse. In *Medicine Update* (Ed. Gupta SB) Assoc Physicians India, Mumbai. 15: 695-699, 2005.
- 620.** Sundar S, Chakravarty J, Agrawal S, Singh RK, Rai M. Visceral Leishmaniasis: Diagnostic Overview. In *Multidisciplinary for Parasites, Vectors and Parasitic Diseases* (Ed. Mas-Coma S). Medimond, Valencia, Spain. Vol 1 pp 37-50, 2004.
- 621.** Sundar S. Management of kala-azar - An update. In *Medicine Update* (Ed. Venkatraman S) Assoc Physicians India, Mumbai. 14: 581-4, 2004.
- 622.** Chakravarty J, Sundar S. Neurological manifestations of HIV infection. In *Neurology Update* (Ed. Misra S). IshitaPrintek, Varanasi. pp200-8, 2004.
- 623.** Sundar S, Rai M, Sahu M, Mehta H. Treatment of kala-azar in India – Current status. In *Medicine Update* (Ed. S Das). 13: 160-5, 2003.
- 624.** Sundar S. Treatment of Visceral Leishmaniasis. In (PK Bhattacharya Ed) *Medicine Update*. Bhabani Offset & Imaging Systems, Guwahati. 7: 704-6, 2003.
- 625.** Sundar S, Chakravarty J, Agrawal S, Rai M. Falciparum Malaria - Myriads of uncommon presentation, In *Medicine Update* 2004. UPICON, Allahabad. pp. 268-74, 2002.
- 626.** Sundar S, Sahu M, Rai M. Antimicrobial resistance – Prevention and cure. In *Medicine Update* (Ed Gupta SB). Assoc Physicians India Mumbai. 12: 1108-15, 2002.
- 627.** Sundar S, Rai M. Advances in the management of Indian visceral leishmaniasis. In *Post-graduate Medicine* (Ed. Das AK), The Assoc. Physicians India, Mumbai. 15: 55-61, 2001.

- 628.** Sundar S. Treatment of kala-azar: Current status. In (Ed. Bhattacharya SK) *Strategies for control of kala-azar and malaria*. Pub Balaji UthanSansthan, Patna. pp.29-35, 2001.
- 629.** Pai K, Agrawal NR, Sundar S. Infections and immunity in old age. In *Frontiers in Geriatric Medicine*, (Ed. Gambhir IJS), Banaras Hindu University, Varanasi. pp 66-74, 2000.
- 630.** Sundar S, M Rai. Diagnosis and treatment of Indian kala-azar in the next millennium. In *Medicine Update* (Ed. MM Singh). Bombay, Assoc Physicians India. 9: 101-10, 1999.
- 631.** Sundar S. Chemotherapy of Indian kala-azar. In *Kala-azar – Round table conference series*. (Eds. Gupta S, Sood OP) Ranbaxy Science Foundation, Gurgaon. pp35-46, 1999.
- 632.** Sundar S, Singh VP. Diagnosis and treatment of kala-azar – Problems and perspectives. In *Medicine Update* 1998 (Eds. P Nigam, AK Thacker, M Misra). Assoc Physician India UP Chapter, Groakhpur. pp. 116-21, 1998.
- 633.** Sundar S, R Shrivastava, NK Agrawal, Singh VP. Infections in the elderly - An overview. In *Trends in Geriatric Medicine* (Eds. Singh DS, Singh AK, Gambhir IJS), Banaras Hindu University, Varanasi. pp228-237,1996.
- 634.** Agrawal NR, Sundar S. Hormone replacement therapy - can it reverse aging. In *Trends in Geriatric Medicine* (Eds. Singh DS, Singh AK, Gambhir IJS), Banaras Hindu University, Varanasi. pp 337-44, 1996.
- 635.** Sundar S, Singh S. Treatment of kala-azar and PKDL: *Recent advances*. *Dermatology Update*. pp15-26, 1995.
- 636.** Sundar S. Drug resistance in Indian kala-azar. In Singh DS, Sundar S, Singh NK ed. *Medicine Update*. Vol IV pp12-20, 1994.
- 637.** Sundar S. Therapeutic strategies in Indian kala-azar, Current Status. In *Medicine Update*, Vol IV (Ed. PK Wahal). ppIII-26-31, 1994.
- 638.** Sundar S, GS Singh, TM Mahapatra, Singh VP, VS Raj, VK Vinayak, N Singla. Immunodiagnosis of kala-azar with special reference to direct agglutination test. In S Kumar, AK Sen, GP Dutta, RK Sharma eds. *Tropical Diseases: Molecular Biology and Control Strategies*. Publication & Inform. Direc., CSIR, New Delhi. pp. 459-62, 1994.
- 639.** Sundar S. Chemotherapy of malaria- current status. In *Internal Medicine update API*, Bihar Chapter. pp95-104, 1993.
- 640.** Sundar S. Cardiac arrhythmias in patients with chronic obstructive pulmonary disease. In *Basic approach to critical care medicine* (Ed. K Tripathi). pp119-129, 1991.

641. Tiwari HK, Sundar S, Kumar A, Vaish SK. Evaluation of oral and intravenous propranolol in patients of essential hypertension. *Proc UPICON*. pp109-112, 1983.
642. Sundar S, Verma DP, Kumar A, Singh VP, Vaish SK. Cardiac arrhythmias in digoxin toxicity. *Proc UPICON* 1983 pp119-121.
-

RESEARCH PAPER/ARTICLES NOT IN PUBMED

643. **Sundar S.** and Nahid E. Visceral Leishmaniasis (Kala-azar) in J. Indian Med Assoc 2020; 118(6): 67-71
644. Shyam Sundar, Jaya Chakravarty & Lalit P Meena (2019) Leishmaniasis: treatment, drug resistance and emerging therapies, *Expert Opinion on Orphan Drugs*, 7:1, 1-10, DOI: [10.1080/21678707.2019.1552853](https://doi.org/10.1080/21678707.2019.1552853)
645. A Singh, A Agarwal, J Chakravarty, S Kumari, M Rai, S Sundar. Predictive Markers of Failure of First Line Anti Retroviral Treatment in HIV Patients in India. *Journal of AIDS & Clinical Research*. 4:210, 2013.
646. Sundar S. What is the purpose of launching the World Journal of Clinical Infectious Diseases ? *World J Clin Infect Dis*. 1(1): 3, 2011.
647. Boelaert M, Bhattacharya S, Chappuis F, El Safi SH, Hailu A, Mondal D, Rijal S, Sundar S, Wasunna M, Peeling RW. Evaluation of rapid diagnostic tests: visceral leishmaniasis. *Nat Rev Microbiol*. (Suppl): S30-S36, 2007.
648. Prakash J, Sundar S, Kar B, Sharma N, Raja R, Usha. Spectrum Of Renal Disease In Visceral Leishmaniasis. *The Internet J Trop Med*. Volume 4 Number 1, 2007.
649. Kumar P, Pai K, Pandey, HP, Sundar S. Study on pinocytosis by monocytes from visceral leishmaniasis patients. *Curr Science*. 83: 631-33, 2002.
650. Sundar S. Visceral leishmaniasis – Need for better drug. *Ann Natl Acad Med Sci*. 38: 147-149, 2002.
651. Singh VP, Sundar S, Rai M, Srinivasan A, Kumar V. The incidence and prevalence of opportunistic infections in patients with HIV/AIDS in developing countries. *J Int Med India*. 4: 41-3, 2001.
652. Sundar S. Resurgence of kala-azar in India: reasons and remedies. *J Int Med ScsAcad* 13: 40-48, 2000.

- 653.** Sundar S. Management of kala-azar in India: Current concepts. *J Ind Acad Clin Med* 4: 104-109, 2000.
- 654.** Sundar S, GS Singh, Singh VP, N Singla, K Kumar, VK Vinayak. Comparative evaluation of DAT, IFAT and micro-ELISA in the serodiagnosis of Indian kala-azar. *J Parasit Dis.* 20: 41-3, 1997.
- 655.** Sundar S. Treatment of visceral leishmaniasis - Current status. *J Assoc Physicians Ind* 45: 640-45, 1997.
- 656.** Singh VP, Sundar S, N Gera, S Gupta, AK Gupta. Clinicopathological profile and therapeutic appraisals in Lymphoma in Eastern UP. *J Assoc Physicians Ind.* 45: 690-2, 1997.
- 657.** Singh N, Nagar S, Roy U, Sundar S, Agrawal S, Rastogi AK. Antigenic analysis of soluble fraction of *L. donovani* by SDS-polyacrylamide gel electrophoresis and immunoblotting. *Ind J Exp Biology.* 33:313-315, 1995.
- 658.** .NR Agrawal, AM Tripathi, TM Mahapatra, Sundar S. Effect of subclinical Malaria on fetal Development. *J ObstGyne India.* 356-60,1994 .
- 659.** Sinha PR, Sundar S, Gupta PR. Two dimensional echocardiographic detection of biventricular thrombi in a case of idiopathic dilated cardiomyopathy. *Amer J Non-invasive Cardiol.* 7: 306-307, 1993.
- 660.** Kumar P, Singh VP, Sundar S and Dey AK. Assessment of physical efficiency level in anaemia. *Ind J Haematology.* 7: 109-12, 1989.
- 661.** Singh DS, Seecatt JS, Sundar S, Dube RK, Singh VP and Gupta JP. Platelet and Fibrinolytic activity in chronic active liver disease. *Ind. J Haematology.* 6: 135-8, 1988.
- 662.** Gambhir IS, Dube R, Singh VP, Singh DS and Sundar S. Paroxysmal Haemoglobinuria. *Ind.J Haematology.* 5: 165, 1987.
- 663.** Agrawal NR, Singh TJ, Sundar S, Bhattacharya SK, Pal D and Tiwari P. Utility of serum gentamycin levels in therapy of UTI. *J Obst. Gynaecol India.*35: 951, 1985.
- 664.** Shyam B, Gulati AK, Sundar Sand Somani PN. Complement fixing antibodies against coxsackie B viruses in clinical carditis. *Ind. J. Med. Microbial.*III: 171-5, 1985.